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Electrogenetherapy of Established B16 Murine Melanoma by
Using an Expression Plasmid for HIV-1 Viral Protein R
Andrea Nicole McCray
Abstract

Novel therapies and delivery methods directed against malignancies such as
melanoma, and particularly metastatic melanoma, are needed. The HIV-1 accessory
protein Vpr (viral protein R) has previously been demonstrated to induce G2 cell
cycle arrest as well as in vitro growth inhibition/killing of numerous tumor cell lines.
In vivo electroporation has been utilized as an effective delivery method for
pharmacologic agents as well as DNA plasmids that express “therapeutic” proteins
and has been targeted to various tissues including malignant tumors. In this study, we
assessed the ability of electroporation-mediated delivery of Vpr plasmid (pVpr) to
induce growth attenuation or complete tumor regression in C57BL/6 mice with
subcutaneous B16.F10 melanoma lesions. To assess the administration of
intratumoral delivery of pVpr with in vivo electroporation, a range of Vpr plasmid
dosages, electroporation parameters, and treatment days were evaluated in a
subcutaneous B16 murine melanoma model. pVpr was injected directly into the
tumors. Immediately following the injection, the subcutaneous tumors were
electroporated. Treatment with 25 µg or 100 µg of pVpr plus electroporation on days
0 and 4 resulted in complete tumor regressions with long-term survival in 14.3% and
viii

7.1% of the mice, respectively. In order to optimize the treatment regimen, B16
tumors were treated on days 0, 2, and 4 with 100 μg pVpr plus electroporation which
resulted in 50% of the mice with complete tumor regressions and long-term survival.
Additional investigations revealed intratumoral Vpr expression and demonstrated that
apoptosis was the mechanism by which Vpr caused tumor regression in vivo. This
study confirmed that treatment with 100 μg of pVpr plus electroporation led to
durable complete regressions in established murine melanoma lesions. The pVpr plus
electroporation treatment regimen has induced complete regressions in mice as well
as resistance to tumor challenge in some of the animals. This is the first
comprehensive study demonstrating the ability of Vpr, when delivered as a DNA
expression plasmid with in vivo electroporation, to induce complete tumor regressions
coupled with long- term survival of mice in a highly aggressive and metastatic solid
tumor model.
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Introduction

Cutaneous Melanoma
Melanoma accounts for only 4% of skin cancers but is responsible for nearly 80%
of the mortality from these cancers, due to metastatic spread (1). Human melanoma
develops from malignant melanocytes that travel to the epidermis (2). Differentiated
melanocytes are located in the basal layer of the epithelium where they produce melanin
(3). A majority of melanomas that are diagnosed are categorized as either melanoma in
situ or superficial spreading melanoma because the lesion originates as a radial growth
phase (2-4). However, some melanomas undergo a vertical growth phase. Nodular
melanoma is the second most common form of melanoma and demonstrates vertical
growth (3-5). A primary melanoma which demonstrates both a tumor thickness greater
than 2 mm and vertical growth has a greater metastatic potential if left untreated than an
in situ melanoma growing in radial phase. Features of metastatic melanoma include
melanin in some portion of the tumor, a nest of malignant cells clumped in one region,
epithelioid and spindle cells (3).
In 2002, the American Joint Committee on Cancer (AJCC) revised the staging
system of melanoma, primary tumor, node, metastasis classification (6,7). According to
the AJCC, stages I and II pertain to primary tumors in which disease has not spread to the
lymph node. Stage III pertains to local lymph node participation and “in transit”
metastases (8). Stage IV involves systemic metastases.

Many prognostic factors for cutaneous melanoma have been examined throughout
the years. The most critical prognostic factors include primary tumor thickness,
ulceration of tumor, number of lymph nodes involved in metastasis, sentinel lymph node
detection of micrometastasis, and regions of distant metastasis (6,7). Certain prognostic
factors are more crucial in predicting survival rates in comparison to other prognostic
factors depending on the stage of disease.
The main prognostic factors that influence survival rates for stage I and II patients
are tumor thickness and ulceration. In stage I disease, surgery can be postponed for more
than three weeks after biopsy without the patient’s five year outcome being adversely
affected (9). Immense tumor thickness is indicative of lower survival rates (10,11).The
more ulcerative a tumor appears, the lower the survival rate (12,13)
Stage III melanoma involves metastasis. Metastasis in the lymph nodes may be
detected at various time points during disease: when primary melanoma is detected; after
treatment of the primary melanoma; or develop without an identified primary melanoma.
No matter which method/route was used for lymph node metastasis to form, survival
rates are not delineated until after the metastasis is discovered (8). The greater the
number of local lymph nodes with metastasis, the lower the survival rate of patients after
10 years (12,14). The Sydney Melanoma Unit/University of Alabama at Birmingham
(SMU/UAB) study demonstrated that Stage III patients with one positive lymph node had
40% survival, whereas patients with greater than 5 positive lymph nodes had only 15%
survival at 10 years (12). Even in Stage III disease, tumor ulceration is a serious problem
in terms of percent survival rates. The important prognostic factors for stage III: number
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of lymph nodes involved in metastasis, an ulcerated primary melanoma, and nodal size
(6,7,12). Systemic interferon therapy enhances the survival rate of stage III patients.
Stage IV patients have more of a problem than the patients in other stages of
disease. Sites of stage IV metastasis include the skin, soft tissue, or remote lymph nodes
for the first sites. A secondary site of metastasis is the lungs. Brain, liver, and bone cancer
can also arise from metastatic melanoma (8). In stage IV, the focus is no longer on the
primary tumor as an indication for survival rates. The main prognostic factor is the
anatomic location of the metastasis (6,7).
Melanoma Markers Detected in Patients
There are a variety of tumor associated markers linked to melanoma. One of these
markers, tyrosinase, is an enzyme involved in the synthesis of melanin. Since tyrosinase
is expressed on normal and malignant melanocytes, it is categorized as an expressed,
nonmutated differentiation antigen similar to MART-1 and gp100. MART-1 is defined as
Melanoma Antigen Recognized by T cells. MAGE-3 is a Melanoma Antigen Gene which
has antigens expressed on only cancer cells and the testis. MUC-18 and p97 are
melanoma-associated antigens.
Tyrosinase, MAGE-3, Muc-18, and p97 were found in individuals with melanoma
by using a multiple-marker assay. The multiple-marker assay involves using RT-PCR to
test peripheral-blood lymphocytes (PBL) for the simultaneous presence of tyrosinase,
MAGE-3, MUC-18, and p97. The multiple-marker assay was first optimized in vitro by
using melanoma cell lines and PBL derived from normal volunteers to examine the
presence of tyrosinase, MAGE-3, MUC-18, and p97. The results demonstrated that all
four melanoma markers were present in at least 80% of the melanoma cell lines and only
3

2 of the normal volunteers had MUC-18(15). By using the same multiple-marker assay
system on PBLs taken from melanoma patients, it was demonstrated that tyrosinase,
MAGE-3, MUC-18, and p97 markers were detected in the melanoma patients. As the
clinical stage of disease evolved from stage I to stage IV, there was a significant
correlation between the number of the aforementioned tumor markers and the stage of
disease. Therefore, stages II, III, and IV melanomas had the most tumor markers. Also,
proteins such as MART-1/Melan-A and gp100 have been detected in lesions from
metastatic patients (16).

Diagnosis of Melanoma
Biopsy and Dermoscopy
Biopsy is a technique used to obtain samples for pathologic diagnosis. Biopsy is
the main method by which suspicious lesions may be diagnosed as melanoma or
nonmelanoma (17). One type of biopsy is an incisional biopsy. An incisional biopsy is
performed by using a scalpel or biopsy punch to extract only a section of the tumor.
During an incisional biopsy, there is removal of the most raised section of the tumor, or
the darkest region if the tumor is flat (17).
A noninvasive procedure used to identify possible melanomas is dermoscopy.
Dermoscopy involves transillumination of the suspected region. Immersion oil is placed
onto the pigmented region and inspected by a dermoscope, which is a lens that has a
transilluminating light source. This procedure enables the physician to visualize
structures underneath the skin surface.
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Issues Concerning the Eradication of a Solid Tumor and
Prevention of Tumor Recurrence
Cancer treatment modalities such as immunotherapy must contend with the issue
of cancer cells evading the immune system, thereby avoiding destruction. In one
scenario, the immune system may not mount an immune response to tumor cells, even
though antigen presenting cells (APCs) may have the capacity to present tumor antigens
but be incapable of reaching T cell regions of the lymph nodes and fail to activate T cells
(18). Another mechanism of tumor evasion is the downregulation of certain molecules
such as MHC molecules or principal tumor antigens. Some tumor cells have developed a
resistance to apoptosis by overexpression of anti-apoptotic proteins or downregulation of
pro-apoptotic proteins (18).
The process of a melanocyte converting into melanoma may be accompanied by
the loss of HLA class I and HLA class II antigens (8). Twenty-one percent of primary
human melanoma cells are deficient in HLA-A2 and/or A28. However, forty-four percent
of human metastatic melanoma cells are deficient in HLA-A2 and/or A28 (19).
There are various categories of human melanoma antigens that are recognized by
T cells. The main divisions of melanoma antigens include antigens mainly expressed by
tumor cells; melanocyte differentiation antigens; antigens that are largely expressed on
tumors; and melanoma specific antigens (20). With the exception of expression on the
testis, there are antigens that are mainly expressed by numerous tumors including
melanoma, which are presented to T cells in the MHC Class I and MHC Class II format
(20). An example of an antigen that is associated with melanoma and other tumors is
MAGE. The MHC class I and class II restricted melanocyte differentiation antigens are
5

expressed on normal and neoplastic melanocytes. Melan-A/MART1 is the more
dominant immunogen among all the melanocyte differentiation antigens. The antigens
that are largely expressed on tumor cells are recognized only by MHC class I restricted T
cells and can be present on both normal and cancerous tissues. p15 and p53 are good
examples of antigens that are largely expressed on tumor cells (20).
The melanoma specific antigens are presented in a MHC class I format to T cells.
An important melanoma specific antigen is tyrosinase-related protein-2 (TRP2). If one of
the common melanoma antigens were very immunogenic, it would possibly be effective
in a melanoma vaccine (20). However, even though melanoma patients may have a
cytotoxic T cell response following previous exposure to melanoma antigenic peptides in
the form of a vaccine, there was no link with clinical responses (21-23). Low survival
rates have been associated with a lack of lymphoid infiltration (24,25).
Many cancer cells possess self antigens that the immune system will not
recognize and attack. Even if cancer cells have some tumor antigens with dominant
epitopes, it remains difficult to find the right combination of antigens such as melanoma
antigens to produce an effective melanoma vaccine. Even though tumor associated
antigens (TAAs) can elicit an immune response, one needs the right combination of
TAAs for efficacy. MART1 and gp100 are two important TAAs for human melanoma.
The major problem with controlling the growth of many solid tumors including
B16.F10 melanoma is that they are poorly immunogenic. Some melanoma tumors
express CD95L also known as FasL (26-28). Some tumor cells elude the immune system
by using their CD95L to attach to CD95 receptor on immune cells and induce cell death
(apoptosis) of the immune cells (29). CD95 and CD95L already exist on B16 melanoma
6

cells. However, exposure to IFN-γ significantly enhanced the expression of CD95 and
CD95L on B16 cells. B16 cells which posses both CD95 and CD95L are primed for
apoptosis (29). In addition, B16 cells do not express MHC class II molecules at all.
However, B16 cells express extremely low quantities of MHC class I (30). Both the
MHC class I and class II molecules can be expressed on B16 cells once the cells are
exposed to IFN-γ (30).
The B16.F10 tumor model is an excellent tumor model to examine the intricacies
of human tumor development/progression and treatment strategies since the B16. F10
tumor is poorly immunogenic. Treatment strategies would have to effectively overcome
the lack of immunogenicity to eradicate the tumor and provide long-term protection
against recurrence.

Alternative Adjuvant Treatment Strategies for Melanoma
Interventional treatment options for melanoma other than surgery are relatively
limited and underscore the need for the development of novel efficacious therapies. Even
after surgical removal of the primary melanoma, patients who had primary melanoma
greater than 4 mm or any form of metastasis are at increased risk of tumor recurrence.
Interferon alpha-2b is administered to patients who have a high risk of melanoma
recurrence (31,32). The FDA approved the use of high dose interferon alpha for adjuvant
therapy after surgery in patients with stage IIB and stage III melanoma. Thus far, high
dose interferon alpha-2b treatment provides significant relapse free survival but cannot
establish overall survival benefits. Since the FDA approved the use of interferon alpha-
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2b, many cancer centers have utilized this therapy. However, there is no widespread
consensus of using interferon alpha-2b throughout the U.S.
IL-2 is another alternative treatment for patients with metastatic melanoma (33).
Even though IL-2 therapy results in rare complete responses (i.e. 8% complete responses
or complete tumor regressions), it is one of the only treatments for metastatic melanoma.
Both interferon alpha and IL-2 are given at doses that have a high potential for toxicity.
Some treatments offer enhanced overall survival for melanoma patients but not
necessarily regression of the tumors. In the animal model, especially in the B16.F10
tumor model, significant growth inhibition is customarily the only attainable goal for
treatment strategies.
Instead of focusing attention on using immunotherapy to recruit the immune
system to eradicate tumors, it may be more beneficial to shift attention to delivering an
agent that will eradicate tumors through intracellular mechanisms and then recruit
immune cells to establish a long-lasting anti-tumor response. One such agent is the Vpr
protein, from HIV-1, which causes apoptosis in various cell lines including cancer cells
(34,35). The other issue concerning eradication of a solid tumor is the choice of the
delivery mechanism. A well-accepted non-viral delivery mechanism is electroporation.
Therefore, in this study, in vivo electroporation was used in order to effectively deliver
plasmid encoding Vpr to B16 solid tumors.

HIV-1 and Vpr
HIV-1 is the etiological agent of AIDS in humans. HIV-1 is a disease that is
obtained through contact with infected blood and sexual contact with an infected person.
8

It is a lentivirus which incorporates its provirus into the genome of the host and uses the
host’s cellular machinery to produce its viral proteins (36). Unlike other retroviruses,
HIV-1 also has six accessory genes in addition to its customary structural genes, gag, pol,
and env (36,37). One accessory gene that is conserved throughout HIV-1, HIV-2, and
SIV is vpr.
Research has shown that HIV-1 causes cell growth arrest and differentiation in
cell culture. Following transfection of a HIV-1 plasmid into TE671 embryonal
rhabdomyosarcoma cells, cell growth arrest occurred within days (38). After almost six
days, the HIV-1 transfected cells were tremendously enlarged in size, completely viable,
and did not replicate (38). The transfected TE671cells continued to show viability in vitro
for at least 3 weeks. Levy et al. (1993) provided the first evidence that HIV-1 has the
capability of inducing cell cycle arrest without cell death as well as the capacity of
inducing cell differentiation.
After various HIV-1 structural genes as well as accessory genes were tested, it
was found that Vpr was responsible for cell growth arrest and differentiation in vitro. In
fact, following exposure to an HIV-1 genome which lacked vpr, transfected
rhabdomyosarcoma cells did not experience growth arrest or substantially differentiate
(38). To examine whether other transformed cells would undergo growth arrest and
differentiation, Levy et al. (1993) transfected human and canine osteosarcoma cells with
vpr plasmid. The vpr-transfected osteosarcoma cells experienced cell growth arrest
without differentiation.
The functions of HIV-1 Vpr are diverse. Depending on the cell type, the functions
of Vpr vary: cell growth inhibition; G2 arrest; influence on tumor growth; differentiation;
9

virus replication in macrophages and non-dividing cells; and transcriptional activation.
Some of the functions of Vpr are beneficial for the survival of HIV within the host and
other functions are tailored for dysregulation of cellular processes in cells other than host
cells i.e. cancer cells. Wong-Staal et al. (1987) made the first assessment that the R open
reading frame encoded for a protein (39). Wong-Staal et al. (1987) translated vpr in
bacteria and discovered that approximately forty percent of HIV infected people had
antibodies against the Vpr protein, demonstrating that a Vpr protein was produced in
vivo. During in vitro cell culture, virus production is undetectable in HIV-infected
peripheral blood cells unless the cells are stimulated by antigen, mitogen, or cytokines
(40-43). vpr augments HIV and SIV replication in T cells and macrophages (44-48).
Ogawa et al. (1989) provided the first evidence that Vpr may be a positive attribute in
terms of HIV replication (46). Data demonstrate that HIV-1 vpr is sufficient to cause
differentiation and growth inhibition in the human rhabdomyosarcoma cells, TE671 (38).
The vpr-transfected TE671 cells underwent differentiation as demonstrated by the cells
becoming large in size, developing branched processes, and being multinucleated. It was
noted that these differentiated cells did not replicate after transfection. The vpr gene also
causes differentiation and growth inhibition in various cell lines such as
rhabdomyosarcoma line RD and osteosarcoma line D17 (38).
Animal Models for HIV-1
The only animals capable of being infected with HIV-1 are humans and
chimpanzees. However, there is currently no reliable animal model for a naturally
occurring HIV-1 infection. Data did show that chimpanzees could be infected with
relatively low doses of HIV, yet there was no long-term damage to the chimpanzees’
10

immune systems (37). In a rare occurrence, high viral loads and a CD4+ T cell depletion
to 100 cell/μl range did arise in one chimpanzee almost a decade after being exposed to
two different HIV strains (HIV-1SF2 and HIV-1LAV-1b). Due to the fact that chimpanzees
are an endangered species that are incapable of progressing to disease in a timely manner
following exposure of virus isolates, they are not sought after as an animal model for
HIV-1 immunodeficiency (49).
Researchers have developed transgenic mice that express HIV-1 genes. These
HIV-1 transgenic mice have copies of proviral DNA in all cells, which characterizes the
in vivo process of the postintegration stage of the HIV-1 life cycle (37). Transgenic mice
have viral genes under the direction of cell or tissue-specific promoters. There are Vpr
transgenic mice.

Functions of Vpr
Apoptosis
The C-terminal domain of Vpr has a consequence on the mitochondria as
evidenced by the expulsion of cytochrome C and apoptosis-inducing factor (AIF) which
induce apoptosis (50). Also, apoptosis arises from the interaction of Vpr with the adenine
nucleotide translocator (ANT) which leads to membrane permeabilization of the
mitochondria (50). Bcl-2 is an anti-apoptotic molecule which impedes mitochondrial pore
formation by interacting with ANT to hinder the binding of Vpr with ANT (51).
However, in intact cells, Vpr protein can overcome the anti-apoptotic property of Bcl-2
(52).
Vpr is a multifaceted protein that induces apoptosis via a caspase-dependent as
11

well as a caspase-independent mechanism. AIF is a hallmark of the caspase-independent
approach to apoptosis (53). In contrast to caspase-independent apoptosis, Vpr causes
apoptosis through caspase-9 activation. Vpr does not operate via the Fas/FasL pathway
(52). p53 is not a requirement for Vpr-mediated apoptosis even in human tumor cells
(34,54).
In rodent cells, Vpr protein induces growth inhibition via G1 arrest and ultimately
apoptosis in a short span of time which leaves cells that can slowly persist in growth (55).
G1 arrest as a consequence of Vpr exposure is a more recent concept that is seen in rodent
cells which have been transfected with Vpr plasmid (55). Throughout the literature
primate cells have been examined and Vpr- mediated apoptosis has either followed G2
arrest or has been independent of Vpr induced G2 arrest. Data suggests that Vpr causes
apoptosis via caspase-9 activity in both rodent and primate cells. The selection of the cell
cycle arrest phase is a species restricted phenomenon, but not the occurrence of apoptosis
(55).

Localization of Vpr
Endogenous Vpr Protein
There are a few sources for HIV-1 Vpr: virion-borne Vpr, endogenous synthesis
of Vpr, and extracellular Vpr. Vpr in the serum is most likely bound to either viral Gag or
anti-Vpr antibodies (56-58). The Gag protein is essential for the assimilation of Vpr
protein into newly developing viral particles (57-59). It is still a question of whether
extracellular Vpr occurs due to disintegration of infected cells or to release from infected
cells (60).
12

Cells that have been transfected with plasmid encoding vpr express Vpr protein
within the cells at sufficient levels. Apoptosis has been observed in various cell lines such
as tumor cell lines after exposure to Vpr protein. Previous research has focused on cells
derived from primates including human cancer cell lines to attest to the apoptotic activity
induced by Vpr. However, even in rodent cells, Vpr protein causes apoptosis via the
degradation of mitochondria and the activation of caspase-9 (55). Rodent cells derived
from hamster and mouse such as BHK and NIH3T3 cells undergo apoptosis after
transfection with Vpr plasmid (55).
Extracellular Vpr Protein
There are various transformed cell lines in which Vpr protein was exported after
transfection with the vpr gene. These transformed cell lines are T cells (H9, Sup T-1),
monocytes (HL60,THP-1), muscle cells (TE671, RD), and neuroblastoma cells (SK-NMC) (56). There are several studies in which purified intracellular Vpr protein penetrates
the cells (61,62).
Bystander Effect
HIV-1 soluble factors such as Vpr have always played a role in the
bystander effect in terms of killing non-Vpr expressing cells during an infection. Studies
have shown various uninfected cells that succumb to apoptosis during HIV infection such
as uninfected CD4+ T cells, thymocytes, lymph node cells, CD8+ T cells, B cells,
macrophages, natural killer cells, and dendritic cells (63-77). The Vpr-mediated
bystander effect is not only demonstrated in primate cell lines or cells involved in active
infection. Vpr protein induces apoptosis in Vpr -transfected rodent cells as well as nontransfected rodent cells grown in the same culture (55).
13

Purified Vpr protein can penetrate cells in vitro (61,62). If purified Vpr can
penetrate cells simply by being in the presence of the cells, there is no reason not to
speculate that Vpr derived from a plasmid can be secreted from transfected melanoma
cells within an established tumor to other cells within that tumor. In this manner, the
enhanced delivery method of intratumoral injection of plasmid encoding Vpr plus
electroporation could lead to Vpr protein being secreted throughout the tumor and leaving
a trail of apoptotic cells in its path. Vpr protein can create ion channels in cell membranes
of live cells (78). Apoptotic attributes occurred in whole cells and purified mitochondria
after exposure to extracellular Vpr (50,51).
Expression Level Determines Apoptotic or Anti-Apoptotic Attributes of Vpr
Even though the majority of studies point to the apoptotic role of Vpr in a variety
of cell types, there are a minority of studies which indicate an anti-apoptotic role for Vpr.
During the natural course of HIV-1 infection, it is predicted that Vpr expression is low in
order to facilitate survival of the virus. The anti-apoptotic aspect was exhibited in the
early stage of HIV-1 infection (79). Evidence indicates an anti-apoptotic property of Vpr
when Vpr is expressed at low levels. CD4+ T Jurkat cells which continually expressed
low quantities of Vpr were able to resist cell death after exposure to apoptosis-inducing
reagents (80). Also, HEp-2 cells which continually expressed low quantities of Vpr
demonstrated an anti-apoptotic feature (81). Conversely, evidence demonstrates that high
Vpr expression causes apoptosis (54,82-85).

14

Electroporation
In Vitro Electroporation
Electroporation is a transfection method that uses the application of electric pulses
(i.e. electric field) to cause transient permeability of the cell membrane and permits drugs
and plasmids to cross the cell membrane (86,87). DNA was successfully transferred in
vitro to murine lyoma cells which marked the first gene transfer into mammalian cells
using electroporation (86,87). Neumann et al. (1982) greatly enhanced the electricallymediated uptake of DNA in the murine lyoma cells by better optimizing the electric field
strength conditions (high electric fields). The optimum field strength for enhanced DNA
transfer was 8 kV/cm, 5 μs. Further development of this approach led to studies
demonstrating that electric fields could be used to effectively administer a
chemotherapeutic reagent to mammalian cells. The investigators used 1200 V/cm to
deliver chemotherapeutic drugs to B16.F10 cells in vitro (88). In vitro electroporation
enhanced the cytotoxic impact of chemotherapeutic drugs such as bleomycin and
cisplatin on various cell lines especially the B16.F10 cells. Today, laboratories use in
vitro electroporation as a standard procedure for either transfecting cells or transforming
bacteria with plasmid.
In Vivo Electroporation

Electrochemotherapy
Electrochemotherapy (ECT) is the treatment of tumors via the administration of
chemotherapeutic agents in conjunction with electric pulses. Bleomycin is the preferred
chemotherapeutic agent that has been administered in conjunction with electroporation in
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ECT preclinical studies which examined tumor growth inhibition in various solid tumor
models (89-92). Previous ECT experiments have demonstrated that bleomycin has the
greatest decrease in drug concentration necessary to elicit an anti-tumor response (93).
Our laboratory examined an ECT protocol that delivered bleomycin
intratumorally to B16 tumors as opposed to the traditional intravenous delivery of
bleomycin prior to electroporation (94). The findings of this study demonstrated that
intratumoral administration of bleomycin followed by electroporation yields significantly
increased survival of ECT-exposed mice, B16 tumor growth delay, and high objective
response rates which were mainly due to complete responses. Also, the intratumoral
delivery of bleomycin administered between 30 minutes before electroporation and 3
minutes following electroporation offered a better window of opportunity for optimal
electrochemotherapy than the previous intravenous method (94). Even with the improved
intratumoral ECT technique, ECT offers short-term tumor regressions in established B16
tumors with a high incidence of recurrence by day 25 post-treatment (90,94-96). One
plausible explanation for tumor-free ECT-exposed mice experiencing tumor recurrence in
this very aggressive tumor model is that there was residual disease that resulted from
microscopic tumor cells next to or beneath the original treatment site (94). Usually after
ECT treatment of subcutaneous B16 melanoma, there is no long-lasting immunity that
will provide resistance to future tumor challenge (90,94,96).
Additional research combined the methodologies of intratumoral ECT with
intratumoral plasmid delivery plus electroporation (95). GM-CSF plasmid plus
electroporation treatment was performed 24 hours after ECT and resulted in one out of
eight mice achieving a complete B16 regression and resisted challenge with B16 cells in
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the opposite flank for an extra 100 days (95). Sustained B16 tumor regressions were also
obtained following peritumoral treatment with electrochemotherapy combined with IL-2
plus electroporation. In addition, tumors such as mammary tumors and squamous cell
carcinoma regressed as a result of treatment with IL-12 plasmid plus ECT (97). The next
phase of in vivo electroporation was to use electroporation to enhance the delivery of
plasmid expressing a wide range of proteins but mainly cytokines.

Plasmid DNA Delivery plus Electroporation
In vivo delivery of plasmids by electroporation has been used to treat tumors in
animal models. IL-2 or IL-12 plasmid delivered with in vivo electroporation had an
impact on slowing B16 tumor growth (98). IL-2 or IL-12 plasmid was administered with
or without electroporation on only one treatment day. IL-2 or IL-12 plasmid plus
electroporation caused a significant tumor growth delay of about five to fifteen days in
comparison to IL-2 or IL-12 plasmid intratumorally delivered to the B16 tumor without
electroporation. Plasmids encoding for IL-12 and IL-18 delivered with electroporation
inhibited B16 tumor growth in mice (99). When the combination of IL-12 and IL-18
plasmids was administered to the B16 tumors via electroporation, mice had significant
longevity as well as significant reduction in tumor volume in comparison with mice that
were given IL-12 and IL-18 plasmids without electroporation.
There are only a few studies in which a cytokine expression plasmid has caused
complete regression of a subcutaneous B16 tumor. Treatment with IL-12 plasmid plus
electroporation caused established B16.F10 melanoma lesions to completely regress
which resulted in high cure rates (100,101). The electrode design, the electric field
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strength, and the treatment days were the major parameters involved in the antiproliferative activity of the electrically-mediated delivery of IL-2, IL-12, and IL-12/IL-18
plasmids. Therefore, the studies in which over 40% of the mice had complete regression
resulted from the use of a penetrating electrode that rotated 1500 V/cm around the tumor
on multiple treatment days (100,101). The aforementioned parameters will have to be
determined in any future electrogenetherapy protocol.
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Objectives

The HIV-1 Vpr protein has a variety of roles in cell cycle arrest and apoptosis of
numerous cell types especially cancer cell lines in vitro. However, the in vivo activity of
HIV-1 Vpr has not been closely examined in terms of tumor growth inhibition and tumor
regression in a solid tumor model particularly in the context of a non-viral delivery
method. For this reason, studies were initiated to examine the effects of electricallymediated intratumoral Vpr plasmid delivery into subcutaneous B16 melanoma in
C57/BL6 mice. The B16.F10 melanoma grows very aggressively and has a deficiency in
MHC I molecules which makes this tumor poorly immunogenic (29). Therefore, a
successful Vpr plasmid plus electroporation treatment regimen against B16 melanoma
should work at the early time points after initiation of treatment and cause long-term
tumor-free survival in treated mice.
The hypothesis of this work: Intratumoral delivery of a Vpr expression plasmid
administered with in vivo electroporation will lead to growth inhibition and regression of
established B16.F10 melanoma in syngeneic C57BL/6 mice.
This is the first description of the ability of a plasmid expressing HIV-1 Vpr,
when delivered by in vivo electroporation, to cause complete regression of an aggressive
metastatic tumor such as melanoma. In order to characterize the anticancer mechanism of
Vpr, the following aims have been proposed.
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Specific Aim 1
To Determine the Optimal pVpr Dosage and Electroporation Parameters Required for
Tumor Reduction
Electrogenetherapy enhances protein expression following delivery of a plasmid
that encodes the protein of interest. In this manner, Vpr protein would be more effectively
expressed once pVpr has been administered by in vivo electroporation. Several dosages
ranging from 25 μg to 200 μg of pVpr in combination with electroporation will be
examined in order to determine the appropriate dosage of pVpr that causes optimum
tumor growth inhibition and/or regression. In addition to the proper pVpr dosage, the
optimum electroporation parameters will be incorporated into the protocol. After
appropriate treatment, tumor growth rates will be evaluated based on tumor volume
calculations. In order to substantiate that Vpr protein is contributing to the tumor
inhibition and/or regression, it will be necessary to examine Vpr expression following
electrically mediated delivery of pVpr to tumors. Vpr protein will be detected by
immunohistochemical staining of tumors excised at time points prior to regression.

Specific Aim 2
To Elucidate a Mechanism Regarding the Ability of Vpr to Inhibit Tumor Growth In Vivo
Previous in vitro studies have shown that Vpr induces apoptosis in a variety of
cancer cells; similarly pVpr plus electroporation may reduce B16 tumor volume in mice
through induction of apoptosis. The elucidation of the tumor inhibitory mechanism will
involve the use of the TUNEL assay. The TUNEL assay will be used to determine
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apoptosis in tumor-bearing mice after the mice have received various pVpr treatment
regimens.

Specific Aim 3
To Investigate whether pVpr Induces an Immune Response, which would allow the
Treated Mice to be Resistant to Tumor Challenge
Previous research has demonstrated that following electrically- mediated delivery
of certain chemotherapeutic agents or cytokine expressing plasmids, the B16.F10 tumors
recur at the original site of regression. However, there have been successful treatments
administered with electroporation that have yielded long-term complete B16 tumor
regression without tumor recurrence, cured mice. In the scenarios in which long-term
tumor regression occurs, mice are challenged with parental B16.F10 cells on the flank
opposite to the one which was originally treated. If cured mice are able to resist challenge
with parental cells then an immune system component may be associated with the
treatment. If any mice are cured following treatment with pVpr plus electroporation, they
will be injected with B16.F10 melanoma cells on the opposite flank and monitored for
tumor growth at the challenge site.

21

Methods

Mice
C57BL/6 mice, the murine strain syngeneic for the B16.F10 melanoma tumor cell
line, were used in this study and were purchased from the National Cancer Institute
(NCI). Mice were housed and maintained during this study in accordance with AALAM
guidelines.

Tumor Cells
The B16.F10 murine melanoma cell line (CRL 6475) was originally purchased
from ATCC and was maintained for studies as monolayers in culture in 90% McCoy’s
medium supplemented with 10% fetal bovine serum (FBS). For the preparation of single
cell suspensions, monolayer of cells were detached from flasks using trypsin-EDTA
(0.05% trypsin-0.53 mM EDTA), centrifuged, washed and resuspended at the proper
concentration for injection in the tumor induction experiments described below.

Subcutaneous Tumor Implantation and Measurements
Tumors were induced by subcutaneous injection of 1x106 B16.F10 cells which
were prepared as described above (viability of cells was greater than 90% as measured by
Trypan blue exclusion) into the left flanks of C57BL/6 mice. Tumors were allowed to
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grow to the appropriate size of at least 29 mm3 but could be larger (depending on the
experiment) before commencement of the treatment regimen. A tumor volume of at least
29 mm3 has been determined to be an ideal minimal size for intratumoral injection since
the administered treatment volume is retained effectively within the lesion with no
significant leakage, providing confidence that the entire dose had been administered.
Tumor volumes were measured before and at periodic intervals following treatment using
a digital caliper by measuring the longest diameter (a) and the next longest diameter (b)
perpendicular to (a). Using those measurements the tumor volume was calculated by the
formula: V = ab2x π/6. The mice were followed in each experiment until the defined endpoint was reached or until tumor volume was determined to be 1300 mm3 (at which point
any mice had usually succumbed to tumor burden or were euthanized due to the size of
the tumor).

Plasmid DNA
The pVpr was a gift from Dr. David Weiner. pVpr encodes the Vpr protein under
the control of a CMV promoter. pcDNA3.1 is the non-coding control plasmid
(Invitrogen). Plasmids were prepared using an endotoxin-free procedure (Qiagen,
Valencia, CA) and suspended in sterile physiological saline.

Anesthesia
Mice were anesthetized by putting them in an induction chamber permeated with
2.5% isoflurane and 97.5% oxygen. Anesthesia was supplied to the mice via a rodent
mask.
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Intratumoral Delivery of Plasmid plus In Vivo Electroporation
Tumors were treated intratumorally with the specified dosage of the Vpr plasmid
(pVpr) or control / backbone plasmid vector (pcDNA3.1) depending on the experiment.
Subsequently, tumors from the appropriate groups were subjected to in vivo
electroporation using a custom-made applicator containing 6 penetrating electrodes that
was inserted into the tissue around the tumor. Depending on the treatment group, electric
pulses were administered using a BTX T820 pulse generator (BTX/Harvard Apparatus,
Hollister, MA) and autoswitcher (Genetronics, San Diego, CA). The optimum
electroporation parameters were 1500 V/cm, 100 μs, 6 pulses. These electroporation
parameters were previously described in other studies by our group and were selected
because of their less stringent parameters coupled with the ability to elicit a significant
biological effect.
Treatments were administered on selected days depending on the electroporation
protocol used in the experiment. For the treatment groups P+ or P– indicates with or
without treatment with the pVpr and E+ or E- indicates with or without electroporation,
respectively. V+ or V- indicates with or without the control “backbone” vector
(pcDNA3.1), respectively.
The mean tumor volume was calculated for each group at selected time points
after the treatment regimen. Additional quantitative measurements made during the study
were fold increase in tumor volume compared to day 0 as well as percent of mice
undergoing complete tumor regression coupled with long-term survival.
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Immunohistochemistry
Tumors were excised at selected time points after treatment and snap frozen.
Tumors were sliced into 5 μm sections. Sections were fixed in ice cold methanol for 10
minutes. Non-specific antigens were blocked in 3% BSA/PBS/Triton X-100 for one hour
at room temperature. Sections were blocked in mouse BD Fc Block in 3%
BSA/PBS/Triton X-100 for one hour (BD Pharmingen). The sections were stained with
the polyclonal Vpr antibody (diluted 1:2000) for one hour at room temperature. Then
sections were incubated with Alexa Fluor 594, a PE-conjugated secondary antibody
(diluted 1: 8000) (Molecular Probes, Inc.). Sections were stained with Hoechst to identify
the nuclei. The sections were visualized using a fluorescent microscope.

TUNEL Assay
For each treatment group, the same tumor sample was used to prepare consecutive
sections for immunohistochemistry and the TUNEL assay. TUNEL refers to Terminal
transferase dUTP nick end labeling which allows for the detection of apoptosis. Sections
were fixed in ice cold methanol for 10 minutes. Apoptosis was assessed using the TACS
in-situ kit TdT-Fluorescein (R & D Systems). Tumor sections were treated with
proteinase K for one hour at room temperature. A TUNEL reaction mixture containing
TdT biotinylated nucleotides was added to each section and incubated in a humidified
chamber for one hour at 37 °C. The biotinylated nucleotides were incubated with a
streptavidin-fluorescein conjugate and visualized using a fluorescent microscope. The
sections were also stained with Hoechst.
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Statistical Analysis
Statistical analysis was conducted using the Student’s t-test. p < 0.05 was
determined to be statistically significant.
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Results

Specific Aim 1
To Determine the Optimal pVpr Dosage and Electroporation Parameters
Required for Tumor Reduction

Preliminary Studies on Vpr Expression and B16 Tumor Growth Inhibition
Numerous preliminary experiments were conducted in order to set parameters to
ascertain pivotal information that would lay the foundation for addressing the specific
aims of this research project. In many instances, the total number of animals used in the
preliminary experiments was small because these experiments were merely designed to
test a hypothesis such as whether there would be protein expression after electricallymediated delivery of plasmid or whether B16 tumor growth inhibition would occur as a
consequence of electrically-mediated delivery of pVpr. The experiments for the optimal
pVpr regimens have higher n values ranging from 10-14 mice after duplicate experiments
were conducted.
The preliminary experiments addressed a wide range of issues such as the
selection of the most effective electroporation parameters for delivery of pVpr and Vpr
protein expression. The initial experiments involved selecting the parameters for the
appropriate pVpr dosage, effective electroporation conditions, elevated Vpr expression,
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and optimal treatment days that would cause the most reduction of B16 tumor in the
mouse model. In particular, B16 tumors were treated with dosages ranging from 25 μg to
200 μg of pVpr plus electroporation in order to determine which dosage would yield the
most tumor growth inhibition. Four different electroporation parameters were examined
in order to determine which parameters would cause the highest Vpr protein expression.
The electroporation parameters were as follows: 100 V/cm, 150 ms; 200 V/cm, 20 ms;
800 V/cm, 5 ms; and 1500 V/cm, 100 μs. Similar electroporation parameters that were
used to confirm Vpr expression were also used to determine which parameters would
effectively deliver pVpr to the B16 tumor.
Another key factor in establishing a pVpr plus electroporation treatment protocol
was the schedule of treatment days. Preliminary experiments involved using the initial
treatment regimen in which treatments were administered on days 0 & 4. Following some
revisions in the schedule, tumor-bearing mice were later treated daily or on alternating
treatment days to obtain more tumor reduction and/or tumor regression than the day 0 &
4 treatment regimen. The individual parameters examined in the preliminary experiments
to effectively deliver an optimal pVpr dosage with the appropriate electroporation
conditions on particular treatment days would be combined for future experiments to
electrically-mediate the delivery of pVpr and yield the highest Vpr expression along with
tumor reduction and/or regression. The key for the following experiments: + or - = with
or without, P= pVpr, V= pcDNA3.1 (non-coding vector), and E = electroporation.
Confirmation of Intratumoral Expression of Vpr in B16 Melanoma Lesions
Initial studies were conducted to confirm Vpr expression and to determine the
kinetics of protein expression. As part of this evaluation, different electroporation
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parameters (i.e. field strength and pulse width) were tested. Tumor-bearing mice were
treated with a single injection of pVpr followed by electroporation. One-hundred
micrograms of pVpr was chosen to study the time course for Vpr protein expression.
Following treatment, four tumors per group were excised at day 2 and day 4. The tumors
were subjected to immunohistochemistry using the polyclonal Vpr antibody. The
treatment groups were as follows: Group 1: P-E+ saline 1500 V/cm, 100 μs; Group 2:
P+E- 100 μg pVpr; Group 3: P+E+ 100 μg pVpr 100 V/cm, 150 ms; Group 4: P+E+ 100
μg pVpr 200 V/cm, 20 ms; Group 5: P+E+ 100 μg pVpr 800 V/cm, 5 ms; Group 6: P+E+
100 μg pVpr 1500 V/cm, 100 μs. Figure 1 depicts intratumoral Vpr staining of a tumor
excised on day 2 post-treatment. At day 2 post-treatment, the saline + 1500 V/cm, 100 μs
treated tumors have non-specific staining (Figure 1A). There is Vpr expression after
delivery of pVpr without electroporation (Figure 1B). In comparison to pVpr delivered
without electroporation, there is greater distribution of Vpr protein throughout the tumor
section following delivery of pVpr plus 1500 V/cm, 100 μs (Figure 1F). The other
electroporation conditions yielded minimal Vpr protein expression (Figure 1C-E). Figure
2 depicts intratumoral Vpr staining of a tumor excised on day 4 post-treatment. At day 4
post-treatment, there is only non-specific staining for the tumors treated with saline plus
1500 V/cm, 100 μs (Figure 2A). The tumors treated with pVpr without electroporation
did not have Vpr expression at day 4 post-treatment (Figure 2B). At day 4, there is still
no detectable Vpr protein expression for any of the other electroporation conditions
(Figure 2C-E). By day 4 post-treatment, the tumors treated with 100 μg pVpr plus 1500
V/cm, 100 μs no longer demonstrate Vpr protein expression (Figure 2F).
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Figure 1. B16.F10 Intratumoral Immunohistochemical Staining with Vpr Antibody on
Day 2 Post-Treatment. All Fields Examined at 20X Magnification. (A) P-E+ Saline 1500
V/cm, 100 μs; (B) P+E- 100 μg pVpr; (C) P+E+ 100 μg pVpr 100 V/cm, 150 ms; (D)
P+E+ 100 μg pVpr 200 V/cm, 20 ms; (E) P+E+ 100 μg pVpr 800 V/cm, 5 ms; (F) P+E+
100 μg pVpr 1500 V/cm, 100 μs. Representative Tumor of Four Tumors.
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Figure 2. B16.F10 Intratumoral Immunohistochemical Staining with Vpr antibody on
Day 4 Post-Treatment. All Fields Examined at 20X Magnification. (A) P-E+ Saline 1500
V/cm, 100 μs; (B) P+E- 100 μg pVpr; (C) P+E+ 100 μg pVpr 100 V/cm, 150 ms; (D)
P+E+ 100 μg pVpr 200 V/cm, 20 ms; (E) P+E+ 100 μg pVpr 800 V/cm, 5 ms; (F) P+E+
100 μg pVpr 1500 V/cm, 100 μs. Representative Tumor of Four Tumors.
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The electroporation parameter 1500 V/cm, 100 μs was chosen as the best
electroporation parameter because it yielded the highest protein expression at day 2 posttreatment. Therefore, 1500 V/cm, 100 μs was used in order to determine the appropriate
pVpr dosage that would cause tumor reduction after delivery of pVpr with
electroporation.
B16 Growth Inhibition Following pVpr plus Electroporation Treatments on Day 0 and
Day 4
Initial studies were conducted to examine tumor reduction following the selected
regimen of treatment on day 0 and day 4. In the context of day 0 and day 4 treatments, it
was necessary to determine which pVpr dosage would be the most efficacious in
reducing B16 tumor volume. Tumor-bearing mice were treated with pVpr dosages
ranging from 25 μg to 200 μg administered with or without electroporation. Treatments
were administered on Day 0 and Day 4. The mice in the electroporation groups received
1500 V/cm, 100 μs. The groups were as follows: Group 1: No Treatment; Group 2: P+E25 μg pVpr; Group 3: P+E+ 25 μg pVpr; Group 4: P+E- 50 μg pVpr; Group 5: P+E+ 50
μg pVpr; Group 6: P+E- 100 μg pVpr; Group 7: P+E+ 100 μg pVpr; Group 8: P+E- 200
μg pVpr; Group 9: P+E+ 200 μg pVpr; Group 10: V+E- 200 μg pcDNA3.1; and Group
11: V+E+ 200 μg pcDNA3.1. The mean tumor volumes for the groups ranged from 3254 mm3.
The mean fold increase values for pVpr +E+ treated tumors were reduced in
comparison to some of the other treatment groups (Figure 3A and Figure 3B). Day 15 is
the end point for the mean fold increase curve because this is the last time point at which
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a majority of untreated mice were alive for analysis. The mean fold increase values were
27.44, 17.81, 12.67, 27.81, and 9.01 for mice treated with P+E- 25 μg pVpr, P+E- 50 μg
pVpr, P+E- 100 μg pVpr, P+E- 200 μg pVpr, and V+E- 200 μg pcDNA3.1, respectively
(Figure 3A). The mean fold increase value for untreated mice was 24.58. The mean fold
increase values for mice treated with P+E+ 25 μg pVpr, P+E+ 50 μg pVpr, P+E+ 100 μg
pVpr, P+E+ 200 μg pVpr, and V+E+ 200 μg pcDNA3.1 were 16.63, 9.36, 7.89, 10.05,
and 11.99, respectively (Figure 3B). By day 15, the group that received P+E+ 100 μg
pVpr had the lowest mean fold increase value (i.e. 7.89) when compared to untreated
mice as well as all other treatment groups. At day 15 post-treatment, the mice treated
with 100 μg pVpr plus electroporation had a significant reduction in tumor volume (p <
0.05) in comparison to untreated mice and mice treated with 25 μg pVpr without
electroporation. A significant difference in tumor reduction could not be established
between any of the electroporation groups.
Even though a difference in treatment efficacy could not be established between
the electroporation groups treated with various dosages of pVpr+ E+ (25 μg to 200 μg
pVpr) or pcDNA+E+ (200 μg), the group that received 100 μg pVpr +E+ was the only
group that had significant tumor reduction compared to untreated mice. Therefore, the
100 μg pVpr dosage with electroporation was further evaluated in the following growth
inhibition studies in order to enhance the growth inhibitory effect.
As a follow-up to the initial study in which Vpr protein expression was examined
after utilizing various electroporation parameters, electroporation parameters were further
evaluated for the ability to induce tumor growth attenuation. Treatments were conducted
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Figure 3A. Various pVpr Dosages Administered without Electroporation to B16
Melanoma
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Figure 3B. Various pVpr Dosages Administered with Electroporation to B16 Melanoma
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on day 0 and day 4. Average tumor volumes ranged from 29-47 cubic millimeters. There
were six mice per group. The groups were as follows: Group 1: P-E+ saline with 1500
V/cm, 100 μs (electric pulses only); Group 2: P+E- 100 μg pVpr; Group 3: P+E+ 100 μg
pVpr 100 V/cm, 150 ms; Group 4: P+E+ 100 μg pVpr 200 V/cm, 20 ms; Group 5: P+E+
100 μg 800 V/cm, 375 μs; Group 6: P+E+ 100 μg pVpr 1500 V/cm, 100 μs. The mice
that were treated with only electric pulses had a mean survival time of 14.33 days. Mice
that were treated with 100 μg pVpr plus 1500 V/cm, 100 μs had a mean survival time of
18.17 days. The group that received 100 μg pVpr plus 1500 V/cm, 100 μs lived
significantly (p<0.05) longer than mice given electric pulses only and mice that received
100 μg pVpr without electroporation (Figure 4). The remaining treatment groups had
mean survival times of 14, 15, and 15.50 days for 100 V/cm, 150 ms; 200 V/cm, 20 ms;
and 800 V/cm, 375 μs, respectively.
At the early time point of day 8, the 100 μg pVpr plus 1500 V/cm, 100 μs treated
tumors had the lowest tumor volumes compared to tumors treated with 100 μg pVpr
without electroporation and all the other 100 μg pVpr with electroporation groups (Figure
5). The tumors treated with 100 μg pVpr without electroporation had lower tumor
volumes than all the other 100 μg pVpr with electroporation groups at this early time
point. By day 15 post-treatment the mean fold increase values for the pVpr plus 1500
V/cm group were similar to the other pVpr plus electroporation conditions.
In terms of increasing survival time for tumor-bearing mice, 100 μg of pVpr
delivered with 1500 V/cm, 100 μs 6 pulses of electroporation worked better than its
counterpart without electroporation and electric pulses alone. In fact, there was enhanced
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Figure 4. Percent Survival Curve for Tumor-Bearing Mice Treated with pVpr plus
Various Electroporation Parameters
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Figure 5. B16 Tumor Growth Responses to pVpr Delivered with Various Electroporation
Parameters
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gene expression in tumors treated with 100 μg pVpr plus 1500 V/cm in comparison to
tumors treated with 100 μg pVpr without electroporation. At the early time points the
other electroporation conditions offered the same tumor growth inhibition as the electric
pulses alone (1500 V/cm, 100 μs). Taken together with the immunohistochemical
staining, this data suggests that the other electroporation conditions did not provide gene
expression perhaps because these conditions did not overcome the threshold level that
would allow for efficient gene delivery. Therefore, the other electroporation parameters
did not provide enough pVpr for efficient Vpr expression to slow tumor growth.
The 1500 V/cm electroporation condition had the greatest impact on tumor
reduction from the onset of the experiment to day 15 post-treatment. It took 15 to 18 days
for 100 μg of pVpr plus 1500 V/cm treated tumors to grow to the same size as the tumors
in the other pVpr plus electroporation conditions. Therefore, it would be best to use 1500
V/cm, 100 μs as the electroporation parameter for future experiments to obtain efficient
gene expression and apoptosis.
To further evaluate and confirm the growth inhibition following delivery of pVpr
with the 1500 V/cm, 100 μs pulsing conditions, another experiment was performed.
Treatments were administered on Day 0 and Day 4. Initial tumor volumes ranged from 37
– 42 cubic millimeters. There was an n=7 for each group. The groups were as follows: no
treatment; 25 μg pVpr+E- ; 25 μg pVpr+E+; 100 μg pVpr+E-; 100 μg pVpr+E+; 100 μg
pcDNA3.1+E-; 100 μg pcDNA3.1+E+; and saline+ E+. By day 7 post-treatment, the
mice treated with either dosage of pVpr+E+ or pcDNA+E+ had lower tumor volumes
than all the other treatment groups including the saline+E+ group. Day 21 was chosen as
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the end point for tumor growth analysis because this is the last day at which untreated
mice were still alive for inclusion in the analysis. The untreated tumors grew so
aggressively that all these mice were overcome by tumor burden. By day 21 posttreatment, the mean fold increase value was 12.21 for the 100 μg pVpr+E+ group. In
contrast, on day 21, the mean fold increase value was 34.98, 31.38, 45.20, 18.24, and
72.60 for the groups 25 μg pVpr+E-, 25 μg pVpr+E+, 100 μg pVpr+E-, 100 μg
pcDNA3.1+E+, and untreated mice, respectively (Figure 6). The 100 μg pcDNA3.1+Egroup and the saline +E+ group were dead after day 18 and were not included in this
analysis. Therefore, by day 21, the 100 μg pVpr+E+ treatment group had the largest
reduction in tumor volume in comparison to the other treatment groups.
Even though the 100 μg pVpr+E+ treated mice had the largest reduction in tumor
volume during the earlier time points, these tumor reductions did not result in high
percentages of long-term complete tumor regressions at latter time points. Of the mice
that were previously treated with 100 μg pVpr+E+, 1 out of 7 mice had complete tumor
regression for over 100 days. Interestingly, 2 out of 7 mice treated with 100 μg
pcDNA3.1+E+ also had complete tumor regression for over 100 days. This type of longterm regression has been previously reported by our group after mice were treated with a
non-coding vector plus electroporation conditions (800 V/cm, 5 ms, 10 pulses) other than
the ones used in the current experiment. However, this preliminary data demonstrated
that intratumoral delivery of 100 μg pVpr consistently slowed B16 tumor growth and
resulted in a long-term complete tumor regression. The results of this preliminary
experiment warranted further investigation of the influence of 25μg pVpr+E+, 100 μg
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Figure 6. B16 Tumor Growth Inhibition Following Treatment with pVpr plus
1500 V/cm, 100 μs
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pVpr+E+, and 100 μg pcDNA3.1 +E+ on B16 growth and regression after day 0 and day
4 treatment. In addition, the anti-proliferative effects of Vpr protein warranted further
investigation into the optimization of the frequency of treatment days.
Treatment with pVpr plus Electroporation on Four Treatment Days
The anti-proliferative effects of Vpr protein were further investigated by
increasing the frequency of treatment days as well as re-evaluating the range of pVpr
dosages that would lead to tumor growth inhibition in the context of these additional
treatment days. To maximize B16 tumor reduction, an experiment was conducted to treat
tumor-bearing mice with various doses of pVpr ranging from 25 μg to 100 μg pVpr
administered with or without electroporation on four treatment days (i.e. days 0, 4, 7, &
11). The appropriate non-coding control plasmid with electroporation, pcDNA3.1, was
used at the 100 μg concentration. There were seven mice per group. The electroporation
parameters were 1500 V/cm, 100 μs. The treatment groups were as follows: Group 1: No
treatment; Group 2: P+E- 25 μg pVpr; Group 3: P+E+ 25 μg pVpr; Group 4: P+E- 50 μg
pVpr; Group 5: P+E+ 50 μg pVpr; Group 6: P+E- 100 μg pVpr; Group 7: P+E+ 100 μg
pVpr; Group 8: V+E- 100 μg pcDNA3.1; Group 9: V+E+ 100 μg pcDNA3.1.
Since there were no complete tumor regressions or partial tumor regressions in
this experiment, the mean tumor doubling time, mean fold increase in tumor volume, and
the mean survival time were determined. The untreated mice had a mean tumor doubling
time of 7.67 days. The mice that received 25 μg pVpr or 50 μg pVpr without
electroporation had mean tumor doubling times of 6.71 and 6.67 days, respectively. The
mice that received 100 μg pVpr without electroporation and 100 μg pcDNA.3.1 without
42

electroporation had mean tumor doubling times of 8.14 and 9.86 days, respectively. The
mice that were exposed to 50 μg pVpr with electroporation had a mean tumor doubling
time of 13.71 days. The mice that were exposed to 100 μg pcDNA.3.1 plus
electroporation had a mean tumor doubling time of 13.14 days. The mice treated with 100
μg pVpr plus electroporation had a mean tumor doubling time of 12.83 days.
Mice that received pVpr or pcDNA3.1 plus electroporation had a reduction in
tumor volume. Day 15 post-treatment is the end point for the mean fold increase curve
because this was the last time point at which more than 40% of untreated mice could be
included for accurate analysis. At day 15, the untreated mice had a mean fold increase of
15.71. At day 15, the mean fold increase value for mice treated with P+E- 25 μg pVpr,
P+E- 50 μg pVpr, P+E- 100 μg pVpr , and V+E- 100 μg pcDNA3.1 was 13.08, 20.19,
18.48, and 15.46, respectively. Also at day 15, the mean fold increase value for mice
treated with P+E+ 25 μg pVpr, P+E+ 50 μg pVpr, P+E+ 100 μg pVpr, and V+E+ 100 μg
pcDNA3.1 was 5.18, 4.35, 4.75, and 5.14, respectively (Figure 7).
Some of the treatment regimens that incorporated electroporation had an impact
on mean survival time of tumor-bearing mice. Untreated mice had a mean survival time
of 14.14 days. Mice treated with P+E- 25 μg pVpr, P+E- 50 μg pVpr, P+E- 100 μg pVpr,
and V+E- 100 μg pcDNA3.1 had mean survival times of 16, 13.71, 18.86, and 17.43,
respectively. Mice treated with P+E+ 25 μg pVpr, P+E+ 50 μg pVpr, P+E+ 100 μg
pVpr, and V+E+ 100 μg had mean survival times of 18.71, 25.86, 21.57, and 20.29. Mice
that were treated with P+E+ 50 μg pVpr and P+E+ 100 μg pVpr were the only groups
that lived significantly (p< 0.05) longer than untreated mice.
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Figure 7. B16 Tumor Growth Attenuation Following Various Dosages of pVpr plus
Electroporation
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Consecutive Treatment Days versus Alternating Treatment Days with pVpr plus
Electroporation
Since subcutaneous B16 tumors grow so aggressively, it was necessary to have
treatments occur at closer intervals to combat tumor growth that would occur between the
treatment days that were previously mentioned such as treatment days 0, 4, 7, and 11. As
part of the evaluation of the anti-proliferative effects of Vpr protein, pVpr plus
electroporation treatments were administered to tumor-bearing mice to determine
whether consecutive treatment days or alternating treatment days would lead to enhanced
tumor growth inhibition. Mice were treated with 100 μg pVpr with 1500 V/cm, 100 μs.
The consecutive treatment days were days 0 and 1. The alternating treatment days were 0
and 2. There was no difference in mean tumor doubling time since both treatment
regimens resulted in a mean tumor doubling time of 8 days. The mean fold increase curve
illustrates the first 11 days because this is the last time point at which the majority
of mice were still alive to obtain an accurate assessment of statistical analysis. In
accordance with the mean fold increase data, at the early time points, the consecutive
treatment regimen caused more reduction in tumor volume than the alternating treatment
regimen. However, by day 8 and 11 post-treatment, the alternating treatment appears
more effective in reducing tumor volume (Figure 8). The preliminary experiments which
examined the effects of delivering pVpr with electroporation on alternating treatment
days resulted in tumor growth inhibition.

45

Figure 8. Growth Attenuation in B16 Tumor Volume Following Treatment with pVpr
plus Electroporation on Alternating Treatment Days
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Therapeutic Benefit of Daily Treatment with pVpr plus Electroporation
In accordance with the data demonstrating the beneficial aspects of tumor
reduction following a consecutive treatment regimen with pVpr plus electroporation, it
was necessary to determine whether there would be additional benefits in extending the
consecutive treatment regimen to include more days. A combination of experiments
were conducted to determine whether daily treatment (i.e. day 0- day 7) would lead to
enhanced tumor reduction and regression after tumor-bearing mice were exposed to 100
μg pVpr plus electroporation. However, this experiment had additional treatment groups
which varied in the days and frequency of treatment administration including the original
treatment regimen of day 0 and day 4. The results represent a combination of two
experiments that were conducted to give a total n of five mice per group with the
exception of the untreated mice and the pcDNA +E+ treated mice. The 100 μg
pcDNA3.1 + E+ group was included in the second experiment as a control group and had
an end-point of 62 days. The treatment groups were as follows: Group 1: P-E+ 1500
V/cm, 100 μs saline twice daily (treatment days 0-7); Group 2: P+E+ 100 μg pVpr 1500
V/cm, 100 μs twice daily (treatment days 0-7); Group 3: P+E+ 100 μg pVpr 1500 V/cm,
100 μs once daily (treatment days 0-7); Group 4: P+E+ 100 μg pVpr 1500 V/cm, 100 μs
on days 0, 2, 4, & 6; Group 5: P+E+ 100 μg pVpr 1500 V/cm, 100 μs on days 0 & 4; and
Group 6: No treatment (n=3); and Group 7: V+E+ 100 μg pcDNA3.1 1500 V/cm, 100 μs
once daily (n= 4).
The various pVpr +E+ treatment regimens extended the lifespan of treated mice.
The untreated tumors grew very aggressively. The mean survival time for untreated mice
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was 11.67 days. Mice treated with 100 μg pVpr plus electroporation twice daily and once
daily had a mean survival time of 146.20 and 122, respectively. Mice treated with 100 μg
pVpr +E+ on days 0 & 4 and mice treated with 100 μg pVpr +E+ on days 0, 2, 4, & 6 had
mean survival times of 28 and 55.60 days, respectively. All of the mice treated once daily
with 100 μg pcDNA3.1 +E+ had a mean survival time of 62 days.
Mice treated with electric pulses administered twice daily had a mean survival
time of 26.80 days. Mice treated with 100 μg pVpr +E+ twice daily lived significantly
longer (p<0.05) than mice treated with 100 μg pVpr +E+ on days 0, 2, 4, & 6; 100 μg
pVpr +E+ on days 0 & 4; saline +electric pulses twice daily; and untreated mice. Mice
treated with 100 μg pVpr +E+ once daily lived significantly longer (p<0.05) than mice
treated with 100 μg pVpr +E+ on days 0 & 4; saline +electric pulses twice daily; and
untreated mice. Mice treated with 100 μg pVpr +E+ on days 0 & 4 lived significantly
longer (p<0.05) than untreated mice. There is no statistical difference between the mean
survival times for the mice treated with pVpr +E+ twice daily or once daily.
Day 21 post-treatment is the end-point for the mean fold increase curve because
this is the last time at which a majority of the saline plus electroporation treated mice
were alive. At day 21 post-treatment, the mice that were treated with 100 μg pVpr plus
electroporation either twice daily or once daily had significant tumor reduction (p<0.05)
in comparison to mice treated with only electric pulses twice daily (Figure 9). There is no
difference between any of the other pVpr+ E+ treatment groups in terms of mean fold
increase values. However, there are differences in pVpr +E+ treatment regimens in terms
of complete tumor regressions. One hundred days after initial treatment, 80% of mice
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receiving either once daily or twice daily intratumoral delivery of 100 μg pVpr with
electroporation were tumor-free. These mice were considered cured. Following
intratumoral delivery of pVpr plus electroporation on Days 0, 2, 4 & 6, one tumorbearing mouse was cured. Tumor volume continued to decrease until all four of the
pcDNA3.1+ E+ treated mice had complete regressions by day 18 post-treatment (Figure
9). The daily pVpr +E+ treatment regimens were more effective than the original pVpr +
E+ treatment regimen of day 0 & day 4 in terms of increasing the longevity of mice as
well as inducing a higher percentage of complete regressions.
Intratumoral pVpr plus Electroporation Administered with a Revised Alternating
Treatment Regimen
Daily treatments offered 80 – 100% complete tumor regressions irrespective of
pVpr + E+ or pcDNA +E+ treatment. Therefore, it was necessary to devise an alternative
treatment regimen that would offer tumor growth inhibitions, complete tumor
regressions, and distinction between pVpr and pcDNA effects. Since the original
alternating pVpr plus electroporation treatment administered on days 0 & 2 yielded
growth inhibition, the concept of administering pVpr with electroporation on alternating
treatment days was revisited with an additional treatment day included. Mice were treated
with 100 μg pVpr plus electroporation on Days 0, 2, and 4. 100 μg pcDNA3.1 plus
electroporation was used as a control. The electroporation parameters were 1500 V/cm,
100 μs. Each group had an n=3. The mice treated with 100 μg pVpr plus electroporation
experienced both a partial response and complete response towards the treatment. From
days 9 through 16 post-treatment, one mouse treated with pVpr plus electroporation had
complete tumor regression until the tumor recurred. There was a slight pcDNA +E+
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Figure 9. Daily Treatment with 100 μg pVpr plus Electroporation Leads to Enhanced
Tumor Reduction
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effect observed at later time points as one pcDNA +E+ treated mouse had complete
tumor regression for 18 days. The mean fold increase curve ends at day 24 because this is
the last time point at which at least two mice are still alive in each group. In comparison
to the pcDNA+E+ treated mice, the mice treated with 100 μg pVpr plus electroporation
had notable growth reduction over the course of the experiment especially from days 9
through 16 post-treatment (Figure 10). There was no difference in the mean survival time
since the mean survival time was 29.0 and 27.3 days for pVpr+ E+ and pcDNA3.1+ E+,
respectively.
Another experiment was conducted to further investigate the initial effect of three
treatments with pVpr+ E+ in the context of the proper control groups. This experiment
had an n=4 mice per group. Treatments were conducted on days 0, 2, and 4. The
electroporation parameters were 1500 V/cm, 100 μs. The treatment groups were as
follows: no treatment; 100 μg pVpr+E-; 100 μg pVpr+E+; 100 μg pcDNA3.1+E-; 100 μg
pcDNA3.1+E+; and saline +E+ (electric pulses alone). The 100 μg pVpr+E+ group had
the most tumor reduction compared to the other treatment groups. In fact, the B16 tumors
grew so aggressively that by day 17 post-treatment, all the groups except for the
untreated group and the 100 μg pVpr+E- group had enough mice still alive for
meaningful statistical analysis. However, mice in the saline+E+ group were dead after
day 17 post-treatment. Therefore, Day 17 was chosen as the end point for the mean fold
increase analysis. The mean fold increase values were 2.17, 46.45, 4.46, and 10.44 for the
group treated with 100 μg pVpr+E+, 100 μg pcDNA+E-, 100 μg pcDNA+E+, and
saline+ E+, respectively (Figure 11). By day 24, one 100 μg pcDNA3.1+ E+ treated
mouse experienced a complete tumor regression that lasted past 100 days post-treatment.
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Figure 10. A Three Treatment Day Regimen Leads to Tumor Volume Reduction
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Figure 11. Three Treatments with 100 μg pVpr Causes Tumor Growth Delay Three
Weeks After Treatment
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Optimal pVpr Treatment Regimen

Optimal pVpr treatment is defined as the treatment regimen that not only yields
tumor growth inhibition but long-term complete tumor regressions as well. Two protocols
from the preliminary experiments yielded either short-term or long-term regressions.
These regimens were further examined as optimal pVpr treatment regimens.

Complete Regression of Established Subcutaneous B16 Tumors After Treatment with
pVpr plus Electroporation
To determine whether there was a therapeutic effect following the delivery of
pVpr with electroporation, post-treatment tumor volume measurements were made to
assess any attenuation of tumor growth as well as the induction of complete tumor
regressions coupled with long-term survival. The average tumor volumes for each group
ranged from 38 – 74 mm3. The electroporation parameters were 1500 V/cm, 100 μs. The
tumors were treated with either 25 μg or 100 μg of pVpr on days 0 and 4 with or without
electroporation. Figure 12 summarizes melanoma tumor growth in the different treatment
groups during the initial 25 days of the experiment. Day 25 post-treatment was chosen as
the end-point for the mean fold increase curve because this is the last time point at which
a majority of the treated mice were still alive for accurate analysis. The absence of a
mean fold tumor volume increase value at day 25 for a particular group indicates that all
of the mice were dead by that time point.
During the first week following treatment, tumor growth was inhibited to some
extent in all the treatment groups when compared to the untreated control group
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(i.e. Figures 12B, C and D versus A). Values for the mean fold increase in tumor volume,
compared to day 0, were indicated for all the treatment groups through day 18 since at
this point at least 50% of all of the mice in each of the treatment groups were still alive
with the exception of 3 (21.4%) mice alive in the untreated group. At day 18 posttreatment the mean fold tumor volume increases were significantly decreased (p<0.05)
for the P+E+ 25 μg pVpr, P+E- 100 μg pVpr, and P+E+ 100 μg pVpr groups with values
of 11.3, 21.2 and 7.6 , respectively, compared to the no treatment group (mean fold tumor
volume increase of 45.4). The value for the P+E- 25 μg pVpr group was not significantly
different to that of the no treatment group. Likewise, at day 18, the V+E- 100 μg
pcDNA3.1 and V+E+ 100 μg pcDNA3.1 groups but not the saline plus electroporation
group were significantly decreased compared to the no treatment group. For the groups
with mean fold tumor volume increase values at day 25 , both the P+E+ 25 μg and P+E+
100 μg pVpr groups had significantly decreased values (i.e. 16.2 and 12.4, respectively)
compared to the V+E+ 100 μg pcDNA3.1 group (i.e. 29) and the P+E- 100 μg pVpr
group (i.e. 74.4). These results indicated an initial backbone vector plus electroporation
effect, in terms of slowing of tumor growth. However, at day 25, the mean fold tumor
volume increases for the pVpr plus electroporation treatment groups were significantly
suppressed compared to the values measured in the pcDNA3.1 control plus
electroporation group.
While tumor reduction is an important evaluative criterion for assessing
therapeutic potential, the critical parameter is the regression of existing tumors, i.e. a
cure. Long-lasting tumor regressions were only observed in the groups that received the
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Figure 12. B16 Melanoma Tumor Growth Responses to pVpr Delivered with or without
In vivo Electroporation. Mean Fold Increase in Tumor Volume (Compared to day 0) at
Various Post-Treatment Time Points for the Different Treatment Groups: (A) No
Treatment; (B) 25 μg pVpr with or without Electroporation; (C) 100 μg pVpr with or
without Electroporation and (D) 100 μg pcDNA3.1 with or without Electroporation and
Saline plus Electroporation. Reprinted, by permission, from Mol Ther 2006; 14:647-55
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pVpr +E+ (Table 1). The 100 μg pVpr+ E+ group had the highest percentage of mice
with complete tumor regressions (42.9%) on day 14 post-treatment. In addition, on day
14 post-treatment, mice that received 25 μg pVpr+ E+ or 100 μg pcDNA3.1+ E+ had
complete tumor regressions in 14.3% and 7.1% of mice, respectively. It is important to
note that the 100 μg pcDNA3.1 +E+ treated mouse that experienced tumor regression
remained tumor free for only 4 days before recurrence of the tumor. At day 28 posttreatment, 14.3% of mice treated with 25 μg pVpr +E+ and 21.4% of mice treated with
100 μg pVpr +E+ had complete tumor regressions. It is important to indicate that none of
the mice in the pcDNA3.1+ E+ treatment group underwent prolonged complete tumor
regression nor did they survive long-term. This finding is presented in Figure 13.
As indicated, the ultimately relevant end-point indicating the anti-tumor efficacy
of the pVpr plus electroporation treatment would be the ability of this regimen to induce
complete tumor regression coupled with long-term survival of the mice, i.e. a cure.
Sustained tumor regression and survival for 100 days post-treatment is considered the
benchmark for cure in mice in this model. Therefore, the survival rate and complete
tumor regression status past 100 days were examined in this study. These data are
presented in the Kaplan-Meier survival curve in Figure 13. Mice in the untreated group as
well as groups receiving 25 μg or 100 μg pVpr without electroporation, pcDNA3.1 with
or without electroporation, and saline plus electroporation all succumbed to tumor burden
with none surviving to the day 100 benchmark. The mean survival time for untreated
mice was 13.6 days. Mice in the untreated group had a significantly shorter survival time
(p<0.05) when compared to groups that received either dose of pVpr+E+ or pVpr+E-,
pcDNA+E+ or pcDNA+E-, & saline+E+. The mean survival time for mice treated
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TABLE 1. Percent of Mice with Complete Tumor Regressions
Groups

Day 14

Day 28

No Treatment

0

N/A

P+E- 25 ug pVpr

0

N/A

P+E+ 25 ug pVpr

14.29% (2 out of 14)

14.29% (2 out of 14)

P+E- 100 ug pVpr

0

N/A

P+E+ 100 ug pVpr

42.86% (6 out of 14)

21.43% (3 out of 14)

V+E- 100 ug pcDNA3.1

0

N/A

V+E+ 100 ug pcDNA3.1

7.14% (1 out of 14)*

0

0

N/A

Saline+E+

N/A indicates that all mice in this group are dead at this time point
* indicates that this mouse only had tumor regression for 4 days before tumor recurred.
Reprinted, by permission, from Mol Ther 2006; 14:647-55
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Figure 13. Kaplan-Meier Survival Curve of Mice in Different Treatment Groups up to
100 Days Post- Treatment
Reprinted, by permission, from Mol Ther 2006; 14:647-55
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with 25 or 100 μg pVpr without electroporation, 100 μg pcDNA without & with
electroporation, or saline plus electroporation (i.e. electric pulses alone) were 17.8, 19.4,
19.3, 24.3 and 17.3 days, respectively. The mean survival times for the groups treated
with 25 or 100 μg pVpr plus electroporation were 40.5 and 43.2 days, respectively. There
was no statistical difference between the mean survival time for mice treated with 25 μg
and 100 μg pVpr plus electroporation.
Delivery of the plasmid with electroporation in the 25 μg or 100 μg pVpr
treatment regimens resulted in complete tumor regression coupled with long-term
survival at least for 100 days in 14.3% and 7.1% of the mice, respectively. Likewise,
there was no statistically significant difference (p<0.05) between the regression/long-term
survival rates in the 25 μg versus 100 μg pVpr plus electroporation treatment groups.

Growth Inhibition and Regression after Multiple Treatments with pVpr plus
Electroporation
Experiments were conducted to examine the anti-tumor effect of electroporationmediated delivery of pVpr administered on multiple treatment days. 100 μg of pVpr or
pcDNA was administered with or without 1500 V/cm, 100 μs on treatment days 0, 2, and
4. The initial mean tumor volumes ranged from 95 -122 mm3. The mean tumor volume
was examined for the various groups for the first eight days after treatment. Day 8 is the
last time point at which at least 50% of the mice were still alive in all the treatment
groups. The mice that were treated with 100 μg pVpr plus electroporation had
tremendous tumor reduction in comparison to the other treatment groups, especially
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the mice treated with 100 μg pcDNA3.1 with electroporation (Figure 14). In addition to
growth attenuation, complete tumor regression was evaluated as an indication of pVpr
treatment efficacy. Twelve days after exposure to pVpr plus electroporation, 50% of the
mice had complete tumor regressions. By day twenty-four post-treatment, 20% (2 out of
10) of pcDNA3.1 plus electroporation treated mice had complete tumor regressions.
Observations were made to determine whether electrically-mediated delivery of
pVpr plus electroporation would prolong survival of tumor-bearing mice. We examined
the survival of mice after the administration of various treatment regimens with the end
point being 100 days after treatment (Figure 15). 50% of the pVpr treated mice that
responded to treatment remained tumor-free for one-hundred days post-treatment. Also,
there were 2 out of 10 mice treated with 100 μg pcDNA3.1 plus electroporation that were
tumor-free for 100 days. The mean survival time for the mice treated with pVpr without
electroporation, pcDNA without electroporation, saline with electroporation (electric
pulses only), and untreated mice was 10.20, 8.90, 13.40, and 8.40 days, respectively. The
mean survival time of mice treated with 100 μg pVpr plus electroporation was 61.80
days. The 100 μg pVpr+ E+ treated mice lived significantly longer (p<0.05) than mice
treated with 100 μg pVpr without electroporation, 100 μg pcDNA3.1 without
electroporation, saline with electroporation, and untreated mice. The mean survival time
for 100 μg pcDNA3.1 +E+ treated mice was 38.60 days. In terms of mean survival time,
there was no statistical difference between mice treated with 100 μg pVpr+ E+ and 100
μg pcDNA3.1+E+.
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Figure 14. Tumor Volume Reduction After Treatment with 100 μg pVpr on Days 0, 2,
and 4

62

Figure 15. Kaplan-Meier Survival Curve After Treatment on Days 0, 2, and 4
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Intratumoral Expression of Vpr In Vivo After Multiple Treatments
Previous immunohistochemistry staining demonstrated Vpr expression at day 2
after a single injection of 100 μg pVpr with electroporation but the protein expression
diminished by day 4. The current experiment was conducted in order to determine
whether multiple treatments of 100 μg pVpr with electroporation would lead to sustained
Vpr expression for several days post-treatment. The multiple treatment regimen involved
administering 100 μg pVpr plus 1500 V/cm, 100 μs on treatment days 0, 2, and 4. The
tumors were sectioned to detect Vpr protein by immunohistochemistry. As early as day 2
post-treatment (1 injection with pVpr plus electroporation on day 0), Vpr protein was
detected (Figure 16A). Multiple treatments with 100 μg pVpr plus electroporation led to
intense expression of Vpr at day 7 post-treatment (after 3 exposures to 100 μg pVpr plus
electroporation) (Figure 16B).
Summary of Specific Aim 1
For the purpose of effectively treating subcutaneous B16 melanoma, certain
treatment parameters had to be elucidated during the preliminary phase of
experimentation. The parameters that had to be tested were the pVpr dosage,
electroporation conditions, Vpr protein expression levels, and the schedule of treatment
days. B16 melanoma lesions were treated with dosages ranging from 25 μg to 200 μg of
pVpr plus electroporation on day 0 and day 4. Only the mice that received 100 μg pVpr
plus electroporation had significant tumor reduction in comparison to the untreated mice.
Therefore, the 100 μg pVpr dosage was chosen as the dosage to be further evaluated in
subsequent growth inhibition studies in conjunction with electroporation.
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Figure 16. Vpr Expression on Day 2 and Day 7 Post-Treatment. (A) Tumor excised at
day 2 post-treatment and stained with PE-conjugated Vpr antibody. (B) Tumor excised at
day 7 post-treatment and stained with PE-conjugated Vpr antibody.
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The next phase of the study examined four different electroporation parameters to
determine which parameters would cause the highest Vpr protein expression after
treatment with 100 μg pVpr +E+ on day 0 & day 4. The electroporation parameters that
were investigated were 100 V/cm, 150 ms; 200 V/cm, 20 ms; 800 V/cm, 5 ms; and 1500
V/cm, 100 μs. Also, it was found that Vpr protein was expressed two days following
treatment and diminished by day 4 following treatment. The electroporation parameters
of 1500 V/cm, 100 μs yielded the highest Vpr expression in comparison to the other
electroporation parameters delivered with electroporation and pVpr alone. In addition to
Vpr expression data, at the early time points (i.e. days 4 and 8), the 100 μg pVpr plus
1500 V/cm, 100 μs treated tumors had the lowest tumor volumes compared to tumors
treated with 100 μg pVpr without electroporation and all the other tumors treated with
pVpr plus various electroporation parameters.
The concentration of pVpr at 100 μg and the electroporation parameters of 1500
V/cm, 100 μs pulses were sufficient to induce B16 tumor reduction but not durable
complete responses. It was anticipated that in order to attain durable complete tumor
regression, the schedule of treatment days would have to be revised. The initial treatment
regimen involved treatments on days 0 & 4 but new avenues would have to be explored
such as daily treatment days or alternating treatment days on the quest to attain complete
regressions. Treatments on days 0, 4, 7 and 11 led to mice that lived significantly (p<
0.05) longer than untreated mice following treatment with P+E+ 50 μg pVpr or P+E+
100 μg pVpr. The four day treatment regimen suggested that closer intervals of treatment
may be necessary to obtain more reduction in tumor volume.
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Closer intervals of treatment were examined with the treatment regimen of
consecutive treatment days (i.e. day 0 and 1) or alternating treatment days (i.e. 0 and 2).
Initially, the consecutive treatment regimen of pVpr +E+ caused more reduction in tumor
volume than the alternating treatment regimen. By the second week after treatment with
pVpr +E+, the alternating treatment appeared more effective in reducing tumor volume.
Since the consecutive treatment (i.e. day 0 and day 1) regimen yielded a reduction
of tumor growth at the early time points, another experiment was conducted to determine
whether daily treatments of pVpr +E+ (i.e. day 0 –day 7) would induce tumor reduction
and complete regression. Daily treatments with 100 μg pVpr + E+ once daily or 100 μg
pVpr + E+ twice daily led to 80% of mice with durable complete tumor regressions. One
mouse had durable complete regression following every other day treatment with 100 μg
pVpr + E+. Also, 100 % of the mice had durable complete regressions after treatment
with 100 μg pcDNA3.1. Since 80- 100 % of mice treated daily with pVpr + E+ or
pcDNA3.1 +E+ had complete regressions, a difference between pVpr and non-coding
vector could not be established. Therefore, in order to possibly differentiate between the
efficacy of pVpr and pcDNA3.1, a revised treatment regimen was devised. The revised
treatment regimen stems from evidence that alternating treatment days of pVpr +E+ led
to tumor reduction with the only modification being an additional day incorporated into
the regimen (i.e. day 0, 2, and 4).
Once the optimal electroporation parameters were found, several main
experiments were conducted to determine the efficacy of tumor reduction and/or
regression as a consequence of using the optimal pVpr dosage as well as the optimal
electroporation parameters. The set of experiments to demonstrate B16 tumor regression
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involved treating mice with 25 μg or 100 μg pVpr plus electroporation. The experiments
were repeated twice for a total n of 14 for the pVpr +E+ and the pcDNA3.1 +E+ group.
By day 14 post-treatment, 42.86% of the mice had complete tumor regressions following
treatment with 100 μg pVpr plus electroporation. Also, by day 14, 14.29% of the mice
had complete tumor regressions following treatment with 25 μg pVpr plus
electroporation. Due to residual tumor cells, tumors recurred in the mice that were treated
with 100 μg pVpr plus electroporation which left 7.14% of these mice with complete
regression past 100 days post-treatment. Whereas, 14.29% of the mice treated with 25 μg
pVpr+E+ maintained regression past 100 days post-treatment.
Another set of experiments were devised from the concepts developed in the
preliminary experiments regarding the alternating treatment regimen (i.e. day 0 and day 2
treatment) for enhanced tumor reduction with tumor regression. The modification in this
set of experiments was that treatment was administered on day 0, 2, and 4. The
experiments were repeated twice for a total n of 10. Mice were treated with 100 μg pVpr
or 100 μg pcDNA3.1 with electroporation. After 100 days post-treatment, 50 % of pVpr
+E+ treated mice and 20% of pcDNA3.1 +E+ treated mice had complete tumor
regressions. Therefore, 100 μg pVpr with 1500 V/cm, 100 μs administered on days 0, 2,
and 4 yielded the highest percentage of durable complete regressions.
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Specific Aim 2
To Elucidate a Mechanism Regarding the Ability of Vpr to Inhibit Tumor Growth In Vivo

Apoptosis is the Mechanism of Tumor Reduction
Previous in vitro studies have demonstrated that Vpr protein induces apoptosis in
a variety of cancer cell lines (54,83). However, there has not been a definitive in vivo
study that shows that Vpr protein induces intratumoral apoptosis and has a role in B16
tumor reduction. The tumors used in this portion of the study were treated according to
the two protocols for the optimal pVpr +E+ treatment regimen. The first protocol
involved treating tumors with the high dose group, 100 μg pVpr +E+ on days 0 and 4.
The second protocol involved treating tumors with 100 μg pVpr +E+ on days 0, 2, and 4.
It was important to determine the in vivo Vpr expression efficiency and any Vpr
induced apoptosis after intratumoral injection of pVpr into established subcutaneous B16
tumors with in vivo electroporation. Initially, to address this issue, melanoma tumors
were excised 48 hours after a single intratumoral treatment with 100 µg of pVpr
delivered with electroporation. After appropriate sectioning and tissue fixation, tumor
sections were stained with a rabbit polyclonal anti-Vpr antibody and a TUNEL reaction
mixture for measurement of protein expression and apoptosis, respectively (Figure 17).
After examination of the sections by fluorescent microscopy under dual filters the areas
of fluorescence, indicative of expression of Vpr and apoptosis, were assessed. Figure 17A
and 17B show tumor sections from pVpr +E+ treatment and pcDNA3.1 +E+ treatment
which were stained with Hoechst reagent, which is a positive control which stains nuclei.
Figures 17C and 17D indicate PE conjugated anti-Vpr antibody staining for the pVpr plus
69

electroporation and pcDNA3.1 control plus electroporation groups, respectively.
Although some background staining is present in the pcDNA3.1 section, staining in the
pVpr section is considerably more extensive and intense indicating expression of Vpr.
Figures 17E and 17F show overlays of the tumor sections indicating Vpr and Hoechst
staining of pVpr plus electroporation and pcDNA3.1 plus electroporation treatment
groups, respectively. The panels in Figures 17G and 17H indicate Hoechst staining for
consecutive sections from the pVpr and pcDNA3.1 treated tumors and serves as the
positive control for nuclei in the TUNEL staining. Finally, Figures 17I and 17J show
TUNEL staining (specifically nuclear staining) of sections from tumors treated with pVpr
plus electroporation and pcDNA3.1 plus electroporation, respectively. This result
demonstrated specific TUNEL staining (fluorescein), indicative of apoptosis, only in the
pVpr plus electroporation treatment group. In summary, the results demonstrate specific
Vpr expression and apoptosis induced by the Vpr DNA construct when delivered
intratumorally, with electroporation, into these aggressive and established subcutaneous
B16.F10 tumors. Overall, the data demonstrate the ability of a plasmid expressing Vpr,
when delivered electroporatively to B16.F10 tumors, to effectively result in long-term
survival of treated mice coupled with complete tumor regression.
Additional studies were conducted to evaluate whether apoptosis is the
mechanism by which Vpr inhibits tumor growth and causes tumor regression in vivo.
Tumors that were exposed to pVpr plus electroporation demonstrated apoptosis as early
as two days post-treatment and continued to undergo apoptosis for a number of days
following treatment (Figure 18). Hoechst was used as a positive control for nuclei in the
PE-conjugated anti-Vpr antibody staining of all the tumor sections. Figure 18 (A-C)
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Figure 17. Day 2 In Vivo Expression of Vpr and Induction of Apoptosis After pVpr
Treatment with Electroporation
Reprinted, by permission, from Mol Ther 2006; 14:647-55
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shows tumor sections from pVpr +E+, pcDNA3.1 +E+, and saline +E+ groups,
respectively. These results show the overlays of the tumor sections indicating expression
of Vpr and Hoechst staining. Figure 18 (D-F) indicates Hoechst staining for sections from
pVpr +E+, pcDNA3.1 +E+, and saline +E+ treated tumors, respectively. Hoechst serves
as the positive control for nuclei in the TUNEL staining. Figures 18 (G-I) show TUNEL
staining of sections from tumors treated with pVpr +E+, pcDNA3.1 +E+, and saline +E+,
respectively. This data showed specific TUNEL staining (fluorescein), which signified
apoptosis, only in the pVpr +E+ treated tumors. Irrespective of multiple treatments,
negligible apoptosis levels, slightly above background levels, were observed in tumors
treated with electric pulses only or 100 μg pcDNA3.1 with electroporation. After three
treatments, 100 μg pVpr alone induced apoptosis but not as efficiently as electroporationmediated delivery of 100 μg pVpr (data not shown).
Summary of Specific Aim 2
The purpose of Specific Aim 2 was to elucidate a mechanism regarding the ability
of Vpr to inhibit tumor growth and cause regression in vivo. Previous in vitro studies
demonstrated Vpr-induced apoptosis. The current study demonstrated for the first time
that Vpr protein caused apoptosis in established B16 tumors. Vpr protein induced
apoptosis as early as two days after the intratumoral delivery of pVpr with
electroporation. Also, sustained apoptosis corresponded to sustained Vpr expression for
up to seven days following intratumoral treatment with 100 μg pVpr +E+ on days 0, 2,
and 4. Data suggest that intratumoral apoptosis is the mechanism by which Vpr protein
causes B16 tumor regression.
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Figure 18. Day 7 Immunohistochemical Staining and Apoptosis Staining of Tumor
Treated with Three Treatments of pVpr+E+
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Specific Aim 3
To Investigate whether pVpr Induces an Immune Response, which would allow the
Treated Mice to be Resistant to Tumor Challenge

Cured Mice Resist B16.F10 Challenge
During the course of conducting research pertaining to electrically-mediated
delivery of pVpr to established melanoma, several mice had durable complete regression,
cured, of cancer. To examine whether these mice were able to resist future exposure to
the parental cancer cells, B16.F10 melanoma cells were injected on the right flank (i.e.
the flank opposite to the one that was originally treated). The initial challenge
experiments involved injecting 1x106 of B16.F10 cells, the original concentration, on the
opposite flank of cured mice. The latter challenge experiments involved injecting 5x105
B16.F10 cells on the opposite flank of cured mice. Cured mice were challenged after
remaining tumor-free for ~ 100 days post-treatment. By using 1x106 or 5x105 B16.F10
cells in some of the challenge experiments, it was determined that the amount of parental
cells does not influence whether cured mice are able to resist tumor challenge. It was
customary to inject naïve C57Bl/6 mice with the same batch of B16.F10 cells that were
used in the challenge experiments as a control for their viability in the cured mice. All
cured mice that resisted tumor challenge were also monitored for continued complete
regression at the original treatment site.
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Cured Mice Resist Tumor Challenge Following Treatment with pVpr plus
Electroporation on Days 0 and 4
Both the low and high dosage pVpr treatment regimen delivered with
electroporation yielded cured mice that were able to resist tumor challenge. Following
treatment with 25 μg of pVpr +E + on days 0 and 4 post-treatment, two out of fourteen
mice were cured. The two 25 μg pVpr +E+ treated mice were challenged with 1x106
B16.F10 cells on the opposite flank (right flank). By day 10 post-challenge, a tumor
appeared at the challenge site on one of the 25 μg pVpr +E+ treated mice, whereas the
other 25 μg pVpr +E+ treated mouse resisted tumor challenge until the end of the time
course at 52 days post-challenge. Following treatment with 100 μg pVpr +E+ on day 0
and day 4, one out of 14 mice were cured. The mouse previously treated with 100 μg
pVpr +E+ was challenged with 1x106 B16.F10 cells on the opposite flank. The 100 μg
pVpr +E+ treated mouse resisted tumor challenge for 41 days post-challenge before a
tumor appeared at the challenge site.
An additional experiment with pVpr +E+ administered on days 0 & 4 yielded
cured mice which were later challenged with B16.F10 cells. One mouse was cured
following treatment with 100 μg pVpr +E+ on days 0 & 4 post-treatment. The 100 μg
pVpr +E+ treated mouse resisted tumor challenge for 54 days post-challenge. Two mice
were cured following treatment with 100 μg pcDNA3.1+ E+. By day 31 post-treatment,
only one of the100 μg pcDNA3.1+ E+ treated mice resisted tumor challenge until day 54
post-challenge.
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Cured Mice Resist Tumor Challenge Following Daily Administration of pVpr plus
Electroporation
Mice that were previously cured after receiving various daily treatments of 100
μg pVpr with or without electroporation were challenged with 1x106 B16.F10 cells on the
right flank. Following treatment with 100 μg pVpr +E+ twice daily, four out of five mice
were cured. Of the cured mice treated with 100 μg pVpr +E+ twice daily, two mice
resisted challenge for the first eleven days post-challenge. By day 16 post-challenge, all
the twice daily pVpr + E+ treated mice succumbed to tumor occurrence at the challenge
site. Four out of five mice treated with 100 μg pVpr +E+ once daily were cured. Only
three of the once daily treated mice were challenged with 1x106 B16.F10 cells because
the other cured mouse in this group was excluded (i.e. euthanized) from the challenge
experiment due to a persistent skin irritation. All three mice treated with once daily pVpr
+E+ were able to resist tumor challenge until the end of the time course at 39 days postchallenge. One mouse was cured following treatment with 100 μg pVpr + E+
administered on days 0, 2, 4, & 6. The mouse previously cured with pVpr +E+ on days 0,
2, 4, & 6 resisted tumor challenge for 39 days post-challenge which was the end point for
this experiment.

Cured Mice Resist Tumor Challenge Following Treatment with pVpr plus
Electroporation on Days 0, 2, and 4
In one of the preliminary experiments, one out of four mice were cured after
receiving day 0, 2, & 4 treatments of 100 μg pcDNA3.1 +E+ and challenged with 5x105
B16.F10 cells on the right flank. However, the pcDNA3.1 +E + treated mouse did not
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resist tumor challenge. Mice that were previously cured after receiving day 0, 2, & 4
treatments of 100 μg pVpr +E+ were challenged with 5x105 B16.F10 cells on the right
flank. Day 50 post-challenge is the end point for the experiment. Following treatment
with 100 μg of pVpr +E + on days 0, 2, and 4 post-treatment, five out of ten mice were
cured. At day 11 post-challenge, four mice resisted tumor challenge. On days 39 to 50
post-challenge, three mice resisted tumor challenge. Following treatment with 100 μg of
pcDNA3.1 +E + on days 0, 2, and 4 post-treatment, two mice were cured. At the day 11
post-challenge time point, one of pcDNA3.1+ E+ cured mice already had a tumor that
had developed for over a week. The other pcDNA3.1+ E+ cured mouse resisted tumor
challenge for 50 days post-challenge.
Summary of Specific Aim 3
The purpose of Specific Aim 3 was to determine whether pVpr induces an
immune response, which would allow the treated mice to be resistant to tumor challenge.
Cured mice were challenged with parental B16.F10 cells after remaining tumor-free for ~
100 days post-treatment. After mice were treated with 25 μg pVpr +E+ or 100 μg pVpr
+E+ on days 0 and 4, 2 out of 14 mice or 1 out of 14 mice resisted tumor challenge,
respectively, for at least 41 days. Three out of five mice and one out of five mice resisted
tumor challenge following pVpr +E+ treatment delivered once daily and every other day,
respectively. Following treatment with pVpr +E+ on days 0, 2, and 4, three out of 10
mice resisted tumor challenge. Following treatment with pcDNA3.1+E+ on days 0, 2,
and 4, one out of 10 mice resisted tumor challenge.
It is important to point out that naïve mice usually develop tumors within one
week of tumor challenge and succumb to tumor burden between days 15 and 20. Also, all
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of the challenged mice survived at least 39 days after challenge. In some instances mice
survived 52 days after challenge. Therefore, the cured mice that were able to resist B16
challenge lived tumor-free for over a month after exposure to the parental B16.F10 cells.
This finding suggests that the pVpr plus electroporation treatment most likely elicited an
immune response which is involved in protecting challenged mice from tumor
development at a time point where there would be significant tumor burden in naïve
animals.
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Discussion
The B16.F10 murine melanoma model was selected for this study because this
tumor cell line has been extensively characterized and is a very good model for many
human malignancies due to its highly invasive and metastatic nature. In particular,
B16.F10 melanoma is a good model for human melanoma because it is poorly
immunogenic due to the lack of MHC I expression and its tumor associated antigens are
recognized as self antigens (29,30). It is difficult to attain complete tumor regressions,
coupled with long-term survival, through therapeutic interventions in established
subcutaneous B16 tumors. The main reason that untreated B16.F10 tumors grow so
aggressively is that mice are incapable of mounting a proper immune response against
this poorly immunogenic tumor.
B16.F10 melanoma is characteristically difficult to treat or cure once visible
tumors have developed. Most researchers are only able to obtain B16 tumor growth delay
for a period of time before the tumor burden necessitates euthanization of the animal.
Typically in this model any therapeutic intervention resulting in only tumor growth delay
is considered to be significant. Usually, untreated B16 tumor-bearing mice die by day 2125 after inoculation of cells. In addition, it is significant that in the current study the
treatment regimen was delivered to established tumors rather than administered either
concomitantly with initial tumor cells or before tumors had visibly formed. The qualities
of B16 melanoma contribute to its attractiveness as a model for human tumors.
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Many investigations have determined that the HIV-1 accessory protein Vpr
induces apoptosis in a large variety of tumor cells in vitro (34,35,102). While many
studies examined the anti-cancer activity of Vpr in vitro concurrent with a mechanism of
cell killing, there was little research to address the anti-cancer effects of Vpr in vivo.
There were a few exceptions in which anti-cancer activity of Vpr was examined in mouse
models.
Eventually, the anti-cancer activity of Vpr was examined in a solid tumor model.
Lentiviral delivery of Vpr to AT-84 oral cancer in a mouse model demonstrated the
capability of Vpr to cause tumor regression (103). In the AT-84 study, low infectivity
rates of lentiviral vector carrying Vpr led to 10% of transfected cells that were apoptotic
in vitro. However, in the AT-84 study, tumors that were exposed to Vpr were shown to
have regions of dead cells but there was no distinction as to whether the dead cells arose
because of necrosis or apoptosis.
There are some safety issues concerning the use of lentiviral vectors in clinical
settings. One negative aspect of using lentiviral vectors is that there could be potential
adverse reactions if multiple lentiviral treatments were administered in an effort to
optimize the treatment regimen. Another negative aspect is that lentiviral delivery could
cause insertional mutagenesis in the host genome (104). The AT-84 study showed the
feasibility of using the Vpr gene product to slow tumor growth and cause tumor
regression in a mouse model. But the study did not provide a gene delivery system that
could be safely translated into future clinical utility. Even though vpr could be inserted
into another viral vector such as an adenoviral vector, in the case of multiple treatment
administrations, it would be difficult to circumvent immune reactions due to multiple
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exposures to the viral vector. An effective non-viral delivery method such as
electroporation would offer a way avoid immune responses to viral vectors.
Specific attention has been focused on the impact that Vpr has on B16.F10 cells.
There was a study that investigated the role of Vpr on B16.F10 tumor cell proliferation in
an animal model but the study was performed by transfecting the B16 cells with Vpr
plasmid prior to injecting the cells into mice. The previous investigation reported that
B16.F10 melanoma cells, when transfected with a plasmid expressing Vpr, were
significantly less efficient in inducing tumor colonies in the lungs of C57BL/6 mice
following intravenous injection (105). The study reported here is the first to investigate
the impact of Vpr on established subcutaneous B16.F10 melanoma.
The hypothesis of this study: Intratumoral delivery of a Vpr expression plasmid
administered with in vivo electroporation will lead to growth inhibition and regression of
established B16.F10 melanoma in syngeneic C57BL/6 mice.
The successful use of electroporation to transfer plasmid to cells in vitro and the
fact that electric fields can be safely and efficiently administered in vivo to deliver small
molecules offered a basis for the delivery of plasmid via in vivo electroporation
(106,107). Several studies have demonstrated that electrically mediated delivery of
plasmids which encode and express therapeutic molecules can be directed efficiently to
tumors. Examples involving experimental melanoma treatment indicated that delivery of
plasmids encoding GM-CSF and IL-2, IL-12 , tumor antigens and IFN-α elicit an antitumor effect (95,98-101,108,109).
In terms of electrogenetherapy, complete tumor regressions of established B16
tumors have been attained mostly with the use of plasmids encoding for cytokines.
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Furthermore, the most efficient transfection method to induce complete B16 regressions
has been in vivo electroporation. Therefore, in vivo electroporation was utilized as a
delivery method in order to maximize the potential for a therapeutic effect of Vpr when
administered as an expression plasmid.
In the study reported here, preliminary data demonstrated that after the
electrically-mediated delivery of pVpr, intratumoral Vpr expression lasted for two days
after a single administration of treatment. It was later discovered that intratumoral Vpr
expression caused intratumoral apoptosis at two days post-treatment. Therefore, various
treatment regimens were explored in order to obtain a sustained level of Vpr expression
while at the same time improving the ability of Vpr to reduce B16 tumor volume and/or
induce complete regression. For these reasons treatment regimens such as daily
treatments (i.e. day 0- day 7) and alternating treatments (i.e. day 0, 2, and 4) were
examined. With the daily treatment regimen there was no way to differentiate between
Vpr induced or non-coding vector induced complete tumor regressions considering that
80 – 100% of treated mice had complete regressions within the same timeframe.
Therefore, the alternating treatment regimen (i.e. day 0, 2, and 4) resulted in 50% of the
mice having complete regressions after pVpr +E+ treatment and 20% of the mice having
complete regressions after pcDNA +E+ treatment. At least with alternating treatments, a
distinction could be made between the time points at which complete regression occurred
for the pVpr +E+ treated mice and the pcDNA + E+ treated mice. Mice treated with pVpr
+E+ on days 0, 2, & 4 had complete tumor regressions by week two after treatment.
Whereas, mice treated with pcDNA +E+ on days 0, 2, & 4 had complete tumor
regressions by 3- 4 weeks after treatment. Thereby, a distinct mechanism of tumor
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regression could be proposed for the pVpr treatment and the non-coding treatment
administered on alternating treatment days. Upon further investigation it was found that
the tumors treated with multiple days of pVpr+ E+ underwent apoptosis, whereas the
tumors treated with multiple days of pcDNA3.1 +E+ did not experience apoptosis.
In this study, Vpr has shown great potential as an anti-tumor agent in terms of
attenuation of B16 tumor growth and complete tumor regressions. During the first twelve
days following treatment, mice that received day 0, 2, & 4 treatments of 100 μg pVpr
with electroporation had substantial reductions in tumor volume in comparison to the
other treatment groups. By day 12 post-treatment, the tumor reductions translated into
complete tumor regressions in 50% of the pVpr plus electroporation treated mice. The
enhanced expression of Vpr correlates with greater apoptosis within the tumor which
would allow for greater reduction in tumor volume.
The Vpr protein is a fast-acting protein which is produced within 48 hours
following a single electrically-mediated pVpr injection. Tumors that were initially treated
with pVpr plus electroporation not only demonstrated apoptosis as early as 48 hours posttreatment but continued to undergo apoptosis for a number of days following three
treatments. After multiple exposures to pVpr plus electroporation, Vpr –induced
apoptosis could possibly enhance the ability of the immune cells to recognize the B16
tumor antigens derived from apoptotic B16 tumors. It is a possibility that after treatment
with pVpr+ E+, there could be improved availability of B16 antigens which might
increase the likelihood that this ordinarily poorly immunogenic tumor would be
recognized by antigen presenting cells which in turn would be engaged by cytotoxic T
cells to destroy the tumor (110,111).
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It is commendable that Vpr had the capability to induce tumor regressions through
an apoptotic-mediated mechanism in the B16.F10 melanoma model which is known for
its highly aggressive nature and tendency to recur even after complete regressions occur.
Therefore, due to its apoptosis-inducing properties, it is anticipated that the pVpr +E+
treatment would be effective in eradicating less aggressive tumors which could result in
higher percentages of complete regressions.
It is important to note that gene delivery via electroporation enhanced the Vpr
gene expression as evidenced by the tumors treated with pVpr +E+ producing a
sufficiently high level of Vpr protein to induce apoptosis. At low levels of expression,
Vpr protein will not cause apoptosis, thereby Vpr protein will exhibit an anti-apoptotic
effect (79,80). There was a possible anti-apoptotic effect exhibited when tumors treated
with pVpr without electroporation expressed Vpr protein but not at sufficiently high
levels to cause apoptosis (data not shown). Even when pVpr was administered without
electroporation on three treatment days, pVpr alone did not cause substantial apoptosis.
Whereas, after a single treatment with pVpr +E+, apoptosis was induced. The current
study definitively showed that the delivery of pVpr via electroporation allowed for a high
level of Vpr protein expression. The high level of Vpr protein expression led to B16
tumor regression which was mediated through apoptosis.
The pVpr + E+ treatment regimen not only eradicates the primary B16 melanoma
but can offer protection against future B16 melanoma development. Once mice had
complete tumor regression for approximately 100 days after treatment they were
considered cured of B16 melanoma. The cured mice were challenged with B16.F10 cells
to determine whether they developed an immune response against the tumor cells. After
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mice were treated with 25 μg pVpr +E+ or 100 μg pVpr +E+ on days 0 and 4, 2 out of 14
mice or 1 out of 14 mice were cured and resisted tumor challenge for at least 41 days.
Following the daily treatment regimen there were some mice that were able to resist
tumor challenge in the groups that were previously cured with once daily 100 μg pVpr
+E+ and every other day with 100 μg pVpr +E+. Following treatment with pVpr +E+ on
days 0, 2, and 4, three out of 10 mice were cured and resisted tumor challenge. Following
treatment with pcDNA3.1+E+, two out of 10 mice were cured but only one of these mice
resisted tumor challenge. Previous studies have indicated that under the right conditions a
high percentage of mice experience long-term protection against parental tumor
following treatment with either an electrically-mediated non-coding vector or CpG-ODN
(112,113). However, in the current study, long-term protection against B16 melanoma
occurred more often in mice cured with one of the pVpr+ E+ treatment regimens as
opposed to the pcDNA3.1 +E+ treatment regimen.
In some instances, there were durable complete regressions observed after
treatment with either pVpr or pcDNA3.1 plus electroporation. The data from the daily
pVpr or pcDNA3.1 plus electroporation treated tumors indicate, even though both
treatment regimens resulted in complete tumor regression, the Vpr exposed tumors
responded by 11-12 days post-treatment in the once daily group, the group that received
pVpr+E+ on days 0, 2, 4, and 6, and group that received pVpr+E+ on day 0, 2, & 4.
Whereas, the pcDNA+E+ treated tumors had complete tumor regression by day 18 -24
days post-treatment. In addition, 50% of the pVpr+ E+ treated mice had regressions from
day 12 post-treatment until day 100 post-treatment with pVpr +E+ on days 0, 2, and 4.
The non-coding vector effect (i.e. pcDNA3.1+ E+) took approximately three weeks to
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cause regression in a minimal number of mice with the remainder of these mice dying by
~ day 30 post-treatment. Even though 2 out of 10 pcDNA+E+ treated mice remained
tumor-free for 100 days, a greater percentage of mice exposed to pVpr +E+ remained
tumor-free for 100 days. The difference in timing of regression and the fact that
pcDNA+E+ treatment induces only minimal intratumoral apoptosis, suggests that Vprinduced tumor regression and pcDNA-induced tumor regression occurs based on two
different mechanisms. A possible mechanism for pcDNA induced regression is
immunostimulatory CpG motifs in the vector backbone.
By using electrically-mediated delivery of plasmid encoding for Vpr or a noncoding plasmid, this research demonstrates two different pathways to induce complete
tumor regression of a poorly immunogenic, aggressive tumor. The first pathway involves
inducing apoptosis via intratumoral Vpr protein expression. The second pathway involves
evoking an immune response against tumor antigens. Interestingly, both pathways result
in lifelong immunity against B16 melanoma in this mouse model.
Previous research involving CpG-ODNs (oligodeoxynucleotides which include
CpG motifs) demonstrated that basic peritumoral injections of CpG-ODNs alone had the
capability of eradicating established tumors and inducing long-term immunity against the
parental tumor (112,114). It is feasible to speculate that electroporation more efficiently
delivers the non-coding plasmid containing CpG motifs directly into the tumor, thereby
possibly allowing eradication of the tumor in a similar manner as the CpG-ODNs. An
earlier electroporation study indicated that delivering non-coding vector with
electroporation caused complete tumor regression and long-term immunity in an
established B16 melanoma (113). An additional study suggests that a possible source of
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tumor regression in non-coding vector treated mice may be immune cell infiltration due
to the CpG motif in the vector (115). Also, perhaps, the more efficient delivery of the
non-coding plasmid induced complete tumor regression in the current study after 2-7
injections of plasmid with electroporation, whereas, the delivery of CpG-ODNs required
15 basic injections to obtain complete tumor regression in a solid tumor (112). Even
though established neuroblastoma is a difficult tumor to treat, the use of CpG-ODNs
offered a way to cure tumor-bearing mice from this solid tumor (112,116). Therefore, the
CpG motifs could contribute to the cure of the B16 solid tumor in the current study.
The mechanism by which CpG-ODNs induce tumor regression involves NK cells,
dendritic cells, macrophages, and T cells. There have been recent investigations
concerning the use of CpG-ODNs in the treatment of melanoma in a pre-clinical
melanoma model (117,118). Delivery of non-coding plasmid with electroporation is less
labor intensive than CpG-ODNs synthesis and may have future utility in treatment of
cancer via non-specific as well as tumor-specific immunity.
This study initially demonstrated the feasibility of using a plasmid encoding for
Vpr delivered by in vivo electroporation to successfully treat established B16 tumors,
which resulted in growth inhibition and ultimately regression. This is the first
comprehensive study demonstrating the ability of Vpr, when delivered as a plasmid via in
vivo electroporation, to induce complete tumor regressions in a solid tumor. Even though
a lentiviral vector carrying Vpr demonstrated tumor regression in AT-84 tumors, there
are safety concerns regarding the use of lentiviral vectors in the clinical setting. The
current study is the first one to deliver pVpr by in vivo electroporation which allows for
multiple treatments without potential immune reactions. As the study continued, it
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showed that the tumor inhibition and regression corresponded to the intratumoral Vprinduced apoptosis. Previous research had only shown Vpr protein expression and its
resultant apoptosis in vitro. The current study offers one of the first evidences which
demonstrate in vivo apoptosis as a result of Vpr protein expression. Also, this study was
the first to demonstrate an optimized treatment regimen by incorporating closer intervals
between treatments in order to attain higher percentages of B16 tumor regressions. In the
future, after additional pre-clinical studies, electrically-mediated pVpr may be efficacious
against human cancer.
The ultimate therapeutic endpoint was complete tumor regression and long- term
survival rather than simply attenuation of tumor growth which has been the benchmark of
most other studies. Therefore, the percentages of the complete tumor regression coupled
with long-term survival attained in this study with pVpr plus electroporation treatment
are biologically significant and warrant further mechanistic studies as well as the
assessment of methods to maximize the anti-tumor effect through the use of different
plasmid doses and Vpr treatment regimens. In addition, once the anti-tumor effect can be
further maximized for the pVpr+ E+ treated mice, potential immune mechanisms, such as
potential presentation of specific melanoma tumor antigens released by the apoptotic
process, could be further investigated. Overall, the data presented underscore the
therapeutic anti-tumor activity of both Vpr and the electroporation delivery method and
suggests a potential clinical utility for this treatment modality against melanomas as well
as possibly other tumor types. In sum, the data suggest that gene delivery using Vpr
provides a way to harness the cell killing potential of Vpr in HIV infected hosts and
utilize it against malignant tumors such as melanomas.
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Future Directions
Completion of this study established an understanding of the anti-tumor effects of
intratumoral delivery of a Vpr expression plasmid mediated through in vivo
electroporation. This study also demonstrated apoptosis as a mechanism of action for Vpr
protein induced tumor regression in the B16 tumor model. This study serves as a
foundation for future studies to investigate the further implications of the capability of
Vpr protein to cause growth inhibition and regression in solid tumors.
Further experiments should be proposed to extend our understanding of how Vpr
induces tumor regression. For example, experiments should be conducted to determine if
and to what extent intratumoral immune cells such as T cells, NK cells, dendritic cells,
and macrophages contribute to tumor regression in B16 tumors that have been treated
with pVpr +E+. Another approach to determine the importance of T-cell mediated
immunity in Vpr induced tumor reduction would be to use a nude mouse model.
It would be interesting to further evaluate whether there are anti-proliferative
effects after the delivery of pVpr plus electroporation in other tumor models especially
human melanoma. In this case, human malignant melanoma cells such as A375 cells
would be injected into nude mice in order to establish a tumor. Subsequently, the A375
tumor would be treated with pVpr+E+. The nude mouse model would provide a way to
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determine the capability of Vpr protein to have anti-tumor activity in the context of the
innate immune system.
It would be interesting to examine other apoptosis-inducing HIV-1 accessory
proteins in the context of the B16 established tumor. Since B16.F10 is highly aggressive,
it would be a good tumor model to test any anti-tumor activity of other HIV-1 accessory
proteins. Experiments could be conducted to determine whether electrically-mediated
delivery of other accessory HIV-1 genes would have the capability to inhibit B16 growth
or cause B16 tumor regression. Thus far, Nef has been shown to cause growth inhibition
in a tumor model (119). It may even be efficacious to combine Vpr with one of the other
HIV-1 accessory proteins to test for synergistic anti-tumor capabilities.
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